<article title='Antidepressant'><paragraph><template><target>Use dmy dates</target><arg name="date">July 2015</arg></template><link><target>File:Prozac.jpg</target><part>thumb</part><part>right</part><part>alt=refer to caption</part><part><link><target>Blister pack</target></link><space/>of Prozac (<link><target>fluoxetine</target></link>), a<space/><link><target>selective serotonin reuptake inhibitor</target></link></part></link><link><target>File:Venlafaxine-3D-balls.png</target><part>thumb</part><part>right</part><part>alt=chemical structure of the SNRI drug venlafaxine</part><part>The chemical structure of<space/><link><target>venlafaxine</target></link><space/>(Effexor), an<space/><link><target>Serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link></part></link><bold>Antidepressants</bold><space/>are drugs used for the treatment of<space/><link><target>major depressive disorder</target></link><space/>and other conditions, including<space/><link><target>dysthymia</target></link>,<space/><link><target>anxiety disorder</target><trail>s</trail></link>,<space/><link><target>obsessive compulsive disorder</target></link>,<space/><link><target>eating disorder</target><trail>s</trail></link>,<space/><link><target>chronic pain</target></link>,<space/><link><target>neuropathic pain</target></link><space/>and, in some cases,<space/><link><target>dysmenorrhoea</target></link>, snoring,<space/><link><target>migraine</target></link>,<space/><link><target>attention-deficit hyperactivity disorder</target></link><space/>(ADHD),<space/><link><target>addiction</target></link>,<space/><link><target>substance dependence</target><part>dependence</part></link>, and<space/><link><target>sleep disorder</target><trail>s</trail></link>. They can be used alone or in combination with other medications but only when prescribed.</paragraph><paragraph>The most important classes of antidepressants are the<space/><link><target>selective serotonin reuptake inhibitors</target></link><space/>(SSRIs),<space/><link><target>serotoninnorepinephrine reuptake inhibitors</target></link><space/>(SNRIs),<space/><link><target>tricyclic antidepressants</target></link><space/>(TCAs),<space/><link><target>monoamine oxidase inhibitors</target></link><space/>(MAOIs),<space/><link><target>RMAO-A inhibitor</target><part>reversible monoamine oxidase A inhibitors</part></link><space/>(rMAO-A inhibitors),<space/><link><target>tetracyclic antidepressant</target><trail>s</trail></link><space/>(TeCAs), and<space/><link><target>noradrenergic and specific serotonergic antidepressant</target></link><space/>(NaSSAs).<extension extension_name='ref' name="SJW and rMAO-A inhibitors 2015"></extension><space/><link><target>Hypericum perforatum#Major depressive disorder</target><part>St John's wort</part></link><space/>is also used in the treatment of depression.<extension extension_name='ref' name="SJW and rMAO-A inhibitors 2015"></extension><extension extension_name='ref' name="SJW Cochrane review"><template><target>cite journal</target><arg name="author"><space/>Linde K, Berner MM, Kriston L<space/></arg><arg name="title"><space/>St John's wort for major depression<space/></arg><arg name="journal"><space/>Cochrane Database Syst Rev<space/></arg><arg name="volume"><space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>CD000448<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18843608<space/></arg><arg name="doi"><space/>10.1002/14651858.CD000448.pub3<space/></arg></template></extension><template><target>TOC limit</target><arg>3</arg></template></paragraph><heading level='2'>Medical uses</heading><paragraph>For depression, the<space/><link><target>Hamilton Depression Rating Scale</target></link><space/>(HAM-D) is often used to measure the severity of depression.<extension extension_name='ref' name="pmid14399272"><template><target>cite journal</target><arg name="author"><space/>Hamilton M<space/></arg><arg name="title"><space/>A rating scale for depression<space/></arg><arg name="journal"><space/>J. Neurol. Neurosurg. Psychiatr.<space/></arg><arg name="volume"><space/>23<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>56–62<space/></arg><arg name="year"><space/>1960<space/></arg><arg name="pmid"><space/>14399272<space/></arg><arg name="pmc"><space/>495331<space/></arg><arg name="doi"><space/>10.1136/jnnp.23.1.56<space/></arg></template></extension><space/>The maximum score for the 17-item HAM-D questionnaire is 52; the higher the score, the more severe the depression.</paragraph><heading level='3'>Major depressive disorder</heading><heading level='4'>Clinical guidelines</heading><paragraph>The UK<space/><link><target>National Institute for Health and Care Excellence</target></link><space/>(NICE) 2009 guidelines indicate that antidepressants should not be routinely used for the initial treatment of mild depression, because the risk-benefit ratio is poor. The guidelines recommend that antidepressant treatment should be considered for:</paragraph><list type='bullet'><listitem>People with a history of moderate or severe depression,</listitem><listitem>Those with mild depression that has been present for a long period,</listitem><listitem>As a second-line treatment for mild depression that persists after other interventions,</listitem><listitem>As a first-line treatment for moderate or severe depression.</listitem></list><paragraph>The guidelines further note that antidepressant treatment should be used in combination with psychosocial interventions in most cases, should be continued for at least 6 months to reduce the risk of relapse, and that SSRIs are typically better tolerated than other antidepressants.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.nice.org.uk/guidance/cg90/chapter/key-priorities-for-implementation<space/></arg><arg name="title">Depression in adults: The treatment and management of depression in adults<space/></arg><arg name="work">NICE guidelines [CG90]<space/></arg><arg name="date">October 2009<space/></arg><arg name="publisher">National Institute for Health and Care Excellence (UK)<space/></arg><arg name="accessdate">23 September 2015</arg></template></extension></paragraph><paragraph><link><target>American Psychiatric Association</target></link><space/>treatment guidelines recommend that initial treatment should be individually tailored based on factors that include severity of symptoms, co-existing disorders, prior treatment experience, and patient preference. Options may include pharmacotherapy, psychotherapy, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS) or light therapy. Antidepressant medication is recommended as an initial treatment choice in people with mild, moderate, or severe major depression, and should be given to all patients with severe depression unless ECT is planned.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://psychiatryonline.org/content.aspx?bookID</arg><arg name="title">PsychiatryOnline &#124; APA Practice Guidelines &#124; Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension></paragraph><heading level='4'>Systematic Reviews</heading><paragraph>Conflicting results have arisen from studies analyzing the efficacy of antidepressants by comparisons to placebo in people with acute mild to moderate depression. Stronger evidence supports the usefulness of antidepressants in the treatment of depression that is chronic (<link><target>dysthymia</target></link>) or severe.</paragraph><paragraph>Researchers<space/><link><target>Irving Kirsch</target></link><space/>and Thomas Moore have contested the pharmacological activity of antidepressants in the relief of depression, and state that the evidence is most consistent a role as active<space/><link><target>placebo</target><trail>s</trail></link>.<extension extension_name='ref' name="administration2002"><template><target>cite journal</target><arg name="title">The emperor's new drugs: An analysis of antidepressant medication data submitted to the U.S. Food and Drug Administration<space/></arg><arg name="author"><space/>Kirsch I, Moore TJ, Scoboria A, Nicholls SS<space/></arg><arg name="journal"><space/>Prevention & Treatment<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="doi"><space/>10.1037/1522-3736.5.1.523a<space/></arg></template></extension><space/>Their study consisted of a meta analysis incorporating data from both published studies and unpublished data obtained from the FDA via a<space/><link><target>Freedom of Information Act</target></link><space/>request. Overall, antidepressant pills worked 18% better than placebos, a statistically significant difference, but not one that is clinically significant.<extension extension_name='ref'><template><target>cite news</target><arg name="url">http://www.usatoday.com/news/health/drugs/2002-07-08-antidepressants.htm<space/></arg><arg name="title">Study: Antidepressant barely better than placebo<space/></arg><arg name="newspaper">USA Today<space/></arg><arg name="date">7 July 2002<space/></arg><arg name="accessdate">6 November 2008</arg></template></extension><space/>In a later publication, Kirsch concluded that the overall effect of new-generation antidepressant medication is below recommended criteria for clinical significance.<extension extension_name='ref' name="pmid18303940"><template><target>cite journal</target><arg name="author"><space/>Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT<space/></arg><arg name="title"><space/>Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration<space/></arg><arg name="journal"><space/>PLoS Medicine<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>e45<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18303940<space/></arg><arg name="pmc"><space/>2253608<space/></arg><arg name="doi"><space/>10.1371/journal.pmed.0050045<space/></arg></template></extension></paragraph><paragraph>Another study focusing on paroxetine (Paxil) and imipramine found that antidepressant drugs were only slightly better than placebo in cases of mild or moderate depression they surveyed but offered &quot;substantial&quot; benefit in those with severe depression.<extension extension_name='ref' name="Fournier JC, DeRubeis RJ, Hollon SD, et al. 4753"><template><target>cite journal</target><arg name="author">Fournier JC, DeRubeis RJ, Hollon SD<space/></arg><arg name="title">Antidepressant drug effects and depression severity: a patient-level meta-analysis<space/></arg><arg name="journal">JAMA<space/></arg><arg name="volume">303<space/></arg><arg name="issue">1<space/></arg><arg name="pages">47–53<space/></arg><arg name="date">January 2010<space/></arg><arg name="pmid">20051569<space/></arg><arg name="pmc">3712503<space/></arg><arg name="doi">10.1001/jama.2009.1943<space/></arg><arg name="url"></arg><arg name="display-authors">etal</arg></template></extension></paragraph><paragraph>In 2014 the U.S. FDA published a systematic review of all antidepressant maintenance trials submitted to the agency between 1985 and 2012. The authors concluded that maintenance treatment reduced the risk of relapse by 52% compared to placebo, and that this effect was primarily due to recurrent depression in the placebo group rather than a drug withdrawal effect.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors">Borges S, Chen YF, Laughren TP, Temple R, Patel HD, David PA, Mathis M, Unger E, Yang P, Khin NA<space/></arg><arg name="title">Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration<space/></arg><arg name="journal">J Clin Psychiatry<space/></arg><arg name="volume">75<space/></arg><arg name="issue">3<space/></arg><arg name="pages">205–14<space/></arg><arg name="year">2014<space/></arg><arg name="pmid">24717376<space/></arg><arg name="doi">10.4088/JCP.13r08722<space/></arg><arg name="url"></arg></template></extension></paragraph><paragraph>A review commissioned by the<space/><link><target>National Institute for Health and Care Excellence</target></link><space/>concluded that there is strong evidence that SSRIs have greater efficacy than placebo on achieving a 50% reduction in depression scores in moderate and severe major depression, and that there is some evidence for a similar effect in mild depression. The treatment guidelines developed in conjunction with this review suggest that antidepressants should be considered in patients with moderate to severe depression and those with mild depression that is persistent or resistant to other treatment modalities.<extension extension_name='ref' name="Depression in Adults update"><template><target>cite web</target><arg name="title">Depression in Adults (update)<space/></arg><arg name="url">http://www.nice.org.uk/nicemedia/pdf/Depression_Update_FULL_GUIDELINE.pdf<space/></arg><arg name="format">PDF<space/></arg><arg name="publisher">www.nice.org.uk<space/></arg><arg name="work">National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Care Excellence<space/></arg><arg name="accessdate">20 November 2013<space/></arg><arg name="pages">282–292</arg><arg name="archiveurl">http://web.archive.org/web/20130612122946/http://www.nice.org.uk:80/nicemedia/pdf/Depression_Update_FULL_GUIDELINE.pdf<space/></arg><arg name="archivedate">12 June 2013<space/></arg></template></extension></paragraph><paragraph>The<space/><link><target>Cochrane Collaboration</target></link><space/>recently performed a systematic review of clinical trials of the<space/><link><target>tricyclic antidepressant</target></link><space/><link><target>amitriptyline</target></link>. The study concluded that in spite of moderate evidence for publication bias, there is strong evidence that the efficacy of amitriptyline is superior to placebo.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Leucht C, Huhn M, Leucht S<space/></arg><arg name="title"><space/>Amitriptyline versus placebo for major depressive disorder<space/></arg><arg name="journal"><space/>Cochrane Database of Systematic Reviews<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="pages"><space/>CD009138<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>23235671<space/></arg><arg name="doi"><space/>10.1002/14651858.CD009138.pub2<space/></arg><arg name="editor1-last"><space/>Leucht<space/></arg><arg name="editor1-first"><space/>C<space/></arg></template></extension></paragraph><paragraph>A 2015 systematic review of add-on therapies for treatment-resistant depression concluded that<space/><link><target>quetiapine</target></link><space/>and<space/><link><target>aripiprazole</target></link><space/>have the strongest evidence-base supporting their efficacy, but they are associated with additional treatment-related side effects when used as an add-on therapy.<extension extension_name='ref' name="Adjunct therapy 2015"><template><target>cite journal</target><arg name="vauthors"><space/>Zhou X, Ravindran AV, Qin B, Del Giovane C, Li Q, Bauer M, Liu Y, Fang Y, da Silva T, Zhang Y, Fang L, Wang X, Xie P<space/></arg><arg name="title"><space/>Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis<space/></arg><arg name="journal"><space/>J Clin Psychiatry<space/></arg><arg name="volume"><space/>76<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>e487–98<space/></arg><arg name="date"><space/>April 2015<space/></arg><arg name="pmid"><space/>25919841<space/></arg><arg name="doi"><space/>10.4088/JCP.14r09204<space/></arg><arg name="quote"><space/>Quetiapine and aripiprazole appear to be the most robust evidence-based options for augmentation therapy in patients with treatment-resistant depression<space/></arg></template></extension></paragraph><paragraph>A 2008 Cochrane Collaboration review on<space/><link><target>St John's wort</target></link><space/>(specifically, any extracts which contain<space/><italics><link><target>hypericum perforatum</target></link></italics>), and a 2015 meta-analytic systematic review by some of the same authors, both concluded that it: has superior efficacy to placebo in treating depression; is as effective as standard antidepressant pharmaceuticals for treating depression; and has fewer adverse effects than other antidepressants. The 2015 meta analysis concluded that it is difficult to assign a place for St. John's wort in the treatment of depression owing to limitations in the available evidence base, including large variations in efficacy seen in trials performed in German-speaking relative to other countries.<extension extension_name='ref' name="SJW and rMAO-A inhibitors 2015"><template><target>cite journal</target><arg name="vauthors"><space/>Linde K, Kriston L, Rücker G, Jamila S, Schumann I, Meissner K, Sigterman K, Schneider A<space/></arg><arg name="title"><space/>Efficacy and acceptability of pharmacological treatments for depressive disorders in primary care: systematic review and network meta-analysis<space/></arg><arg name="journal"><space/>Ann Fam Med<space/></arg><arg name="volume"><space/>13<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>69–79<space/></arg><arg name="date"><space/>February 2015<space/></arg><arg name="pmid"><space/>25583895<space/></arg><arg name="pmc"><space/>4291268<space/></arg><arg name="doi"><space/>10.1370/afm.1687<space/></arg><arg name="quote"><space/>In network meta-analysis, tricyclic and tetracyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), a serotonin-noradrenaline reuptake inhibitor (SNRI; venlafaxine), a low-dose serotonin antagonist and reuptake inhibitor (SARI; trazodone) and hypericum extracts were found to be significantly superior to placebo, with estimated odds ratios between 1.69 and 2.03. There were no statistically significant differences between these drug classes. Reversible inhibitors of monoaminoxidase A (rMAO-As) and hypericum extracts were associated with significantly fewer dropouts because of adverse effects compared with TCAs, SSRIs, the SNRI, a noradrenaline reuptake inhibitor (NRI), and noradrenergic and specific serotonergic antidepressant agents (NaSSAs).&nbsp;... TCAs and SSRIs have the most solid evidence base. Further agents (hypericum, rMAO-As, SNRI, NRI, NaSSAs, SARI) showed some positive results, but limitations of the currently available evidence makes a clear recommendation on their place in clinical practice difficult.</arg></template></extension><extension extension_name='ref' name="SJW Cochrane review"></extension><space/><link><target>Reversible monoamine oxidase A inhibitor</target><trail>s</trail></link><space/>(rMAO-A inhibitors) have also been shown to be an effective drug therapy with greater tolerability than other antidepressants;<extension extension_name='ref' name="SJW and rMAO-A inhibitors 2015"></extension><space/>however, the efficacy of SSRIs, tricyclic, and tetracyclic antidepressants in treating depression is supported by a much larger evidence base compared to other antidepressant drug therapies (i.e., St John's wort, rMAO-A inhibitors,<space/><link><target>serotoninnorepinephrine reuptake inhibitor</target></link>,<space/><link><target>serotonin antagonist and reuptake inhibitor</target><trail>s</trail></link>,<space/><link><target>noradrenaline reuptake inhibitor</target><trail>s</trail></link>, and<space/><link><target>noradrenergic and specific serotonergic antidepressant</target><trail>s</trail></link>).<extension extension_name='ref' name="SJW and rMAO-A inhibitors 2015"></extension></paragraph><paragraph>The 2013 Cochrane Collaboration review on<space/><link><target>physical exercise</target></link><space/>for depression noted that, based upon limited evidence, it is more effective than a control intervention and comparable to psychological or antidepressant drug therapies.<extension extension_name='ref' name="Cochrane exercise depression"><template><target>cite journal</target><arg name="vauthors"><space/>Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, McMurdo M, Mead GE<space/></arg><arg name="title"><space/>Exercise for depression<space/></arg><arg name="journal"><space/>Cochrane Database Syst Rev<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>CD004366<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="pmid"><space/>24026850<space/></arg><arg name="doi"><space/>10.1002/14651858.CD004366.pub6<space/></arg><arg name="quote"><space/>Exercise is moderately more effective than a control intervention for reducing symptoms of depression, but analysis of methodologically robust trials only shows a smaller effect in favour of exercise. When compared to psychological or pharmacological therapies, exercise appears to be no more effective, though this conclusion is based on a few small trials.</arg></template></extension><space/>Three subsequent 2014 systematic reviews that included the Cochrane review in their analysis concluded with similar findings: one indicated that that physical exercise is effective as an<space/><link><target>wikt:adjunct treatment</target><part>adjunct treatment</part></link><space/>with antidepressant medication;<extension extension_name='ref' name="Exercise MDD antidepressant"><template><target>cite journal</target><arg name="vauthors"><space/>Mura G, Moro MF, Patten SB, Carta MG<space/></arg><arg name="title"><space/>Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review<space/></arg><arg name="journal"><space/>CNS Spectr<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>496–508<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>24589012<space/></arg><arg name="doi"><space/>10.1017/S1092852913000953<space/></arg><arg name="quote"><space/>Considered overall, the studies included in the present review showed a strong effectiveness of exercise combined with antidepressants.&nbsp;... Conclusions<br /><space/>This is the first review to have focused on exercise as an add-on strategy in the treatment of MDD. Our findings corroborate some previous observations that were based on few studies and which were difficult to generalize.<sup>41,51,73,92,93</sup><space/>Given the results of the present article, it seems that exercise might be an effective strategy to enhance the antidepressant effect of medication treatments. Moreover, we hypothesize that the main role of exercise on treatment-resistant depression is in inducing neurogenesis by increasing BDNF expression, as was demonstrated by several recent studies.</arg></template></extension><space/>the other two indicated that physical exercise has marked antidepressant effects and recommended the inclusion of physical activity as an adjunct treatment for mildmoderate depression<extension extension_name='ref' name="Exercise depression intervention"><template><target>cite journal</target><arg name="vauthors"><space/>Josefsson T, Lindwall M, Archer T<space/></arg><arg name="title"><space/>Physical exercise intervention in depressive disorders: meta-analysis and systematic review<space/></arg><arg name="journal"><space/>Scand J Med Sci Sports<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>259–272<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>23362828<space/></arg><arg name="doi"><space/>10.1111/sms.12050<space/></arg><arg name="quote"><space/>Physical activity has also become increasingly and firmly associated with improvements in mental health and psychological well-being (Mutrie, 2000; Landers & Arent, 2007). In particular, exercise is believed to be effective in preventing depression and also to significantly reduce depressive symptoms in clinical as well as in nonclinical populations (O’Neal et al., 2000; Landers & Arent, 2007). Several correlational studies show that exercise is negatively related to depressive symptoms (e.g., Galper et al., 2006; Hassmén et al., 2000). Moreover, a considerably large number of intervention studies have by now investigated the effect of various exercise programs on depression and the vast majority of them indicate that exercise significantly reduces depression (e.g., Blumenthal et al., 2007; Martinsen et al., 1985; Singh et al., 1997).&nbsp;... To date, it is not possible to determine exactly how effective exercise is in reducing depression symptoms in clinical and nonclinical depressed populations, respectively. However, the results from the present meta-analysis as well as from seven earlier meta-analyses (North et al., 1990; Craft & Landers, 1998; Lawlor & Hopker, 2001; Stathopoulou et al., 2006; Mead et al., 2009; Rethorst et al., 2009; Krogh et al., 2011) indicate that exercise has a moderate to large antidepressant effect. Some meta-analytic results (e.g., Rethorst et al., 2009) suggest that exercise may be even more efficacious for clinically depressed people.&nbsp;... In short, our final conclusion is that exercise may well be recommended for people with mild and moderate depression who are willing, motivated, and physically healthy enough to engage in such a program.</arg></template></extension><space/>and mental illness in general.<extension extension_name='ref' name="Physical activity intervention"><template><target>cite journal</target><arg name="vauthors"><space/>Rosenbaum S, Tiedemann A, Sherrington C, Curtis J, Ward PB<space/></arg><arg name="title"><space/>Physical activity interventions for people with mental illness: a systematic review and meta-analysis<space/></arg><arg name="journal"><space/>J Clin Psychiatry<space/></arg><arg name="volume"><space/>75<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>964–974<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>24813261<space/></arg><arg name="doi"><space/>10.4088/JCP.13r08765<space/></arg><arg name="quote"><space/>This systematic review and meta-analysis found that physical activity reduced depressive symptoms among people with a psychiatric illness. The current meta-analysis differs from previous studies, as it included participants with depressive symptoms with a variety of psychiatric diagnoses (except dysthymia and eating disorders).&nbsp;... This review provides strong evidence for the antidepressant effect of physical activity; however, the optimal exercise modality, volume, and intensity remain to be determined.&nbsp;... Conclusion<br /><space/>Few interventions exist whereby patients can hope to achieve improvements in both psychiatric symptoms and physical health simultaneously without significant risks of adverse effects. Physical activity offers substantial promise for improving outcomes for people living with mental illness, and the inclusion of physical activity and exercise programs within treatment facilities is warranted given the results of this review.</arg></template></extension><space/>All four systematic reviews called for more research in order to determine the efficacy or optimal exercise intensity, duration, and modality.<extension extension_name='ref' name="Cochrane exercise depression"></extension><extension extension_name='ref' name="Exercise MDD antidepressant"></extension><extension extension_name='ref' name="Exercise depression intervention"></extension><extension extension_name='ref' name="Physical activity intervention"></extension><space/>The evidence for<space/><link><target>brain-derived neurotrophic factor</target></link><space/>(BDNF) in mediating some of the<space/><link><target>neurobiological effects of physical exercise</target></link><extension extension_name='ref' name="epigenome"><template><target>cite journal</target><arg name="author"><space/>Denham J, Marques FZ, O'Brien BJ, Charchar FJ<space/></arg><arg name="title"><space/>Exercise: putting action into our epigenome<space/></arg><arg name="journal"><space/>Sports Med<space/></arg><arg name="volume"><space/>44<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>189–209<space/></arg><arg name="date"><space/>February 2014<space/></arg><arg name="pmid"><space/>24163284<space/></arg><arg name="doi"><space/>10.1007/s40279-013-0114-1<space/></arg><arg name="quote"><space/>Aerobic physical exercise produces numerous health benefits in the brain. Regular engagement in physical exercise enhances cognitive functioning, increases brain neurotrophic proteins, such as brain-derived neurotrophic factor (BDNF), and prevents cognitive diseases [76–78]. Recent findings highlight a role for aerobic exercise in modulating chromatin remodelers [21, 79–82].&nbsp;... These results were the first to demonstrate that acute and relatively short aerobic exercise modulates epigenetic modifications. The transient epigenetic modifications observed due to chronic running training have also been associated with improved learning and stress-coping strategies, epigenetic changes and increased c-Fos-positive neurons&nbsp;... Nonetheless, these studies demonstrate the existence of epigenetic changes after acute and chronic exercise and show they are associated with improved cognitive function and elevated markers of neurotrophic factors and neuronal activity (BDNF and c-Fos).&nbsp;... The aerobic exercise training-induced changes to miRNA profile in the brain seem to be intensity-dependent [164]. These few studies provide a basis for further exploration into potential miRNAs involved in brain and neuronal development and recovery via aerobic exercise.</arg></template></extension><extension extension_name='ref' name="trophic factor signaling"><template><target>cite journal</target><arg name="author"><space/>Phillips C, Baktir MA, Srivatsan M, Salehi A<space/></arg><arg name="title"><space/>Neuroprotective effects of physical activity on the brain: a closer look at trophic factor signaling<space/></arg><arg name="journal"><space/>Front Cell Neurosci<space/></arg><arg name="volume"><space/>8<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>170<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>24999318<space/></arg><arg name="pmc"><space/>4064707<space/></arg><arg name="doi"><space/>10.3389/fncel.2014.00170<space/></arg><arg name="quote"><space/>Moreover, recent evidence suggests that myokines released by exercising muscles affect the expression of brain-derived neurotrophic factor synthesis in the dentate gyrus of the hippocampus, a finding that could lead to the identification of new and therapeutically important mediating factors.&nbsp;... Studies have demonstrated the intensity of exercise training is positively correlated with BDNF plasma levels in young, healthy individuals (Ferris et al., 2007). Resistance exercise has also been shown to elevate serum BDNF levels in young individuals (Yarrow et al., 2010). Moreover, it has been shown that moderate levels of physical activity in people with AD significantly increased plasma levels of BDNF (Coelho et al., 2014).&nbsp;... In humans, it has been shown that 4 h of rowing activity leads to increased levels of plasma BDNF from the internal jugular (an indicator of central release from the brain) and radial artery (an indicator of peripheral release; Rasmussen et al., 2009). Seifert et al. (2010) reported that basal release of BDNF increases following 3 months endurance training in young and healthy individuals, as measured from the jugular vein. These trends are augmented by rodent studies showing that endurance training leads to increased synthesis of BDNF in the hippocampal formation (Neeper et al., 1995, 1996).&nbsp;... Both BDNF and IGF-1 play a significant role in cognition and motor function in humans.&nbsp;... Multiple large-scale studies in humans have shown that serum levels of IGF-1 are correlated with fitness and as well as body mass indices (Poehlman and Copeland, 1990). Furthermore, animal studies have shown that exercise in rats is associated with increased amounts of IGF-1 in the CSF.<space/></arg></template></extension><extension extension_name='ref' name="Organ response"><template><target>cite journal</target><arg name="author"><space/>Heinonen I, Kalliokoski KK, Hannukainen JC, Duncker DJ, Nuutila P, Knuuti J<space/></arg><arg name="title"><space/>Organ-Specific Physiological Responses to Acute Physical Exercise and Long-Term Training in Humans<space/></arg><arg name="journal"><space/>Physiology<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>421–436<space/></arg><arg name="date"><space/>November 2014<space/></arg><arg name="pmid"><space/>25362636<space/></arg><arg name="doi"><space/>10.1152/physiol.00067.2013<space/></arg><arg name="quote"><space/>The Effects of Long-Term Exercise Training<br /><space/>[A] physically active lifestyle has been shown to lead to higher cognitive performance and delayed or prevented neurological conditions in humans (71, 101, 143, 191).&nbsp;... The production of brain-derived neurotrophic factor (BDNF), a key protein regulating maintenance and growth of neurons, is known to be stimulated by acute exercise (145), which may contribute to learning and memory. BDNF is released from brain already at rest but increases two- to threefold during exercise, which contributes 70–80% of circulating BDNF (145).</arg></template></extension><space/>was noted in one review which hypothesized that increased BDNF signaling is responsible for the antidepressant effect.<extension extension_name='ref' name="Exercise MDD antidepressant"></extension></paragraph><paragraph>A study published in the<space/><italics><link><target>Journal of the American Medical Association</target></link></italics><space/>(<italics>JAMA</italics>) demonstrated that the magnitude of the placebo effect in clinical trials of depression have been growing over time, while the effect size of tested drugs has remained relatively constant. The authors suggest that one possible explanation for the growing placebo effect in clinical trials is the inclusion of larger number of participants with shorter term, mild, or spontaneously remitting depression as a result of decreasing stigma associated with antidepressant use.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Walsh BT, Seidman SN, Sysko R, Gould M<space/></arg><arg name="title"><space/>Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing<space/></arg><arg name="journal"><space/>JAMA<space/></arg><arg name="volume"><space/>287<space/></arg><arg name="issue"><space/>14<space/></arg><arg name="pages"><space/>1840–7<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>11939870<space/></arg><arg name="doi"><space/>10.1001/jama.287.14.1840<space/></arg></template></extension><space/>Placebo response rates in clinical trials of complementary and alternative (CAM) therapies are significantly lower than those in clinical trials of traditional antidepressants.<extension extension_name='ref' name="pmid20573327"><template><target>cite journal</target><arg name="vauthors"><space/>Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI<space/></arg><arg name="title"><space/>Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants<space/></arg><arg name="journal"><space/>J Clin Psychiatry<space/></arg><arg name="volume"><space/>71<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>682–8<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20573327<space/></arg><arg name="doi"><space/>10.4088/JCP.10r05976blu<space/></arg><arg name="url"><space/></arg></template></extension></paragraph><paragraph>A 2004 review concluded that antidepressant studies that failed to support efficacy claims were dramatically less likely to be published than those that did support favorable efficacy claims.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lee K, Bacchetti P, Sim I<space/></arg><arg name="title"><space/>Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature Analysis<space/></arg><arg name="journal"><space/>PLoS Medicine<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>e191<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18816163<space/></arg><arg name="pmc"><space/>2553819<space/></arg><arg name="doi"><space/>10.1371/journal.pmed.0050191<space/></arg><arg name="editor1-last"><space/>Clarke<space/></arg><arg name="editor1-first"><space/>Mike<space/></arg></template></extension><space/>Similar results were obtained for a study of publication of clinical trials of antidepressants in children.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E<space/></arg><arg name="title"><space/>Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data<space/></arg><arg name="journal"><space/>The Lancet<space/></arg><arg name="volume"><space/>363<space/></arg><arg name="issue"><space/>9418<space/></arg><arg name="pages"><space/>1341–5<space/></arg><arg name="year"><space/>2004<space/></arg><arg name="pmid"><space/>15110490<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(04)16043-1<space/></arg></template></extension><space/>A 2015 investigation of meta-analyses of antidepressant studies found that 79% of them had &quot;sponsorship or authors who were (pharmacutical) industry employees and/or had conflicts of interest&quot;.<extension extension_name='ref' name="Pharmacutical_COI"><template><target>cite journal</target><arg name="last1"><space/>Shanil Ebrahim</arg><arg name="year"><space/>2015<space/></arg><arg name="title"><space/>Meta-analyses with industry involvement are massively published and report no caveats for antidepressants<space/></arg><arg name="journal"><space/>Journal of Clinical Epidemology<space/></arg><arg name="laysummary"><space/>http://www.scientificamerican.com/article/many-antidepressant-studies-found-tainted-by-pharma-company-influence/<space/></arg><arg name="pmid"><space/>26399904<space/></arg><arg name="doi"><space/>10.1016/j.jclinepi.2015.08.021<space/></arg></template></extension></paragraph><paragraph>A 2012 meta-analysis found that fluoxetine and venlafaxine were effective for major depression in all age groups. The authors also found no evidence of a relationship between baseline severity of depression and degree of benefit of antidepressants over placebo.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1">Gibbons</arg><arg name="first1">RD</arg><arg name="last2">Hur</arg><arg name="first2">K</arg><arg name="last3">Brown</arg><arg name="first3">CH</arg><arg name="last4">Davis</arg><arg name="first4">JM</arg><arg name="last5">Mann</arg><arg name="first5">JJ</arg><arg name="title">Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine.</arg><arg name="journal">Archives of General Psychiatry</arg><arg name="date">June 2012</arg><arg name="volume">69</arg><arg name="issue">6</arg><arg name="pages">572–9</arg><arg name="doi">10.1001/archgenpsychiatry.2011.2044</arg><arg name="pmid">22393205</arg><arg name="pmc">3371295</arg></template></extension></paragraph><heading level='4'>The STAR*D Trial</heading><paragraph>The largest and most expensive study conducted to date, on the effectiveness of pharmacological treatment for depression, was commissioned by the<space/><link><target>National Institute of Mental Health</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study<space/></arg><arg name="url">http://www.nimh.nih.gov/trials/practical/stard/index.shtml<space/></arg><arg name="publisher">National Institute of Mental Health<space/></arg><arg name="accessdate">28 November 2012</arg><arg name="archiveurl"><space/>http://www.webcitation.org/6EszRRSYD<space/></arg><arg name="archivedate"><space/>5 March 2013</arg><arg name="deadurl">yes</arg></template></extension><space/>The study was dubbed &quot;<link><target>STAR*D</target><part>The Sequenced Treatment Alternatives to Relieve Depression</part></link>&quot; (STAR*D) Study. The results<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fava M, Rush AJ, Wisniewski SR, Nierenberg AA, Alpert JE, McGrath PJ, Thase ME, Warden D, Biggs M, Luther JF, Niederehe G, Ritz L, Trivedi MH<space/></arg><arg name="title"><space/>A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report<space/></arg><arg name="journal"><space/>The American Journal of Psychiatry<space/></arg><arg name="volume"><space/>163<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>1161–72<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16816220<space/></arg><arg name="doi"><space/>10.1176/appi.ajp.163.7.1161<space/></arg></template></extension><extension extension_name='ref' name="pmid16554526"></extension><space/>are summarized here.Participants in the trial were recruited when they sought medical care at general medical or psychiatric clinics. No advertising was used to recruit subjects in order to maximize the generalizability of the study results. Participants were required to have a minimum score of 14 point on the Hamilton Depression Scale (HAM-D17) in order to be enrolled in the trial. Generally accepted cutoffs are 717 points for mild depression, 1824 points for moderate depression, and 24 for severe depression.<extension extension_name='ref'>http://www.springer.com/cda/content/document/cda_downloaddocument/9781588299666-c1.pdf?SGWID=0-0-45-802906-p173751812</extension><space/>The average participant baseline HAM-D17 score was 22.<extension extension_name='ref' name="ajp.psychiatryonline.org"><template><target>cite web</target><arg name="url">http://ajp.psychiatryonline.org/data/Journals/AJP/4031/28.pdf<space/></arg><arg name="title">ajp.psychiatryonline.org<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>The pre-specified primary endpoint of this trial was remission as determined by the HAM-D score, with all patients with missing scores rated as non-responders. In the aftermath of the trial, the investigators have presented the results mainly using the secondary endpoint of remission according to the QIDS-SR16 Score, which tend to be somewhat higher.</paragraph><list type='bullet'><listitem>After the first course of treatment, 27.5% of the 2,876 participants reached remission with a HAM-D score of 7 or less and 33% achieved remission according to the QIDS-SR scale. The response rate according to the QIDS-SR16 score was 47%. Twenty-six percent dropped out.<extension extension_name='ref' name="pmid16390886"><template><target>cite journal</target><arg name="author"><space/>Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M<space/></arg><arg name="title"><space/>Evaluation of Outcomes with Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice<space/></arg><arg name="journal"><space/>American Journal of Psychiatry<space/></arg><arg name="volume"><space/>163<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>28–40<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16390886<space/></arg><arg name="doi"><space/>10.1176/appi.ajp.163.1.28<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Warden D, Trivedi MH, Wisniewski SR, Davis L, Nierenberg AA, Gaynes BN, Zisook S, Hollon SD, Balasubramani GK, Howland R, Fava M, Stewart JW, Rush AJ<space/></arg><arg name="title"><space/>Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report<space/></arg><arg name="journal"><space/>Am J Psychiatry<space/></arg><arg name="volume"><space/>164<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>1189–97<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17671281<space/></arg><arg name="doi"><space/>10.1176/appi.ajp.2007.06071225<space/></arg></template></extension></listitem><listitem>After the second course of treatment, 21 to 30% of the remaining 1,439 participants remitted.<extension extension_name='ref' name="pmid16554526"><template><target>cite journal</target><arg name="author"><space/>Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, Ritz L, Nierenberg AA, Lebowitz BD, Biggs MM, Luther JF, Shores-Wilson K, Rush AJ<space/></arg><arg name="title"><space/>Medication Augmentation after the Failure of SSRIs for Depression<space/></arg><arg name="journal"><space/>New England Journal of Medicine<space/></arg><arg name="volume"><space/>354<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1243–52<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16554526<space/></arg><arg name="doi"><space/>10.1056/NEJMoa052964<space/></arg></template></extension><space/>Switching medications can achieve remission in about 25% of patients.<extension extension_name='ref' name="ajp.psychiatryonline.org"></extension><extension extension_name='ref' name="pmid16554525"><template><target>cite journal</target><arg name="author"><space/>Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M<space/></arg><arg name="title"><space/>Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression<space/></arg><arg name="journal"><space/>New England Journal of Medicine<space/></arg><arg name="volume"><space/>354<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1231–42<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16554525<space/></arg><arg name="doi"><space/>10.1056/NEJMoa052963<space/></arg></template></extension></listitem><listitem>After the third course of treatment, 17.8% of the remaining 310 participants remitted.<template><target>Citation needed</target><arg name="reason">Not discussed in references above</arg><arg name="date">May 2014</arg></template></listitem><listitem>After the fourth and last course of treatment, 10.1% of the remaining 109 participants remitted.<template><target>Citation needed</target><arg name="reason">Not discussed in references above</arg><arg name="date">May 2014</arg></template></listitem><listitem>Relapse within 12 months was 33% in those who achieved remission in the first stage, and 42% to 50% in those achieving remission in later stages. Relapse was higher in those who responded to medication but did not achieve remission (5983%) than in those who achieved remission.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Rush AJ, Trivedi MH, Wisniewski SR<space/></arg><arg name="title">Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report<space/></arg><arg name="journal">Am J Psychiatry<space/></arg><arg name="volume">163<space/></arg><arg name="issue">11<space/></arg><arg name="pages">1905–17<space/></arg><arg name="date">November 2006<space/></arg><arg name="pmid">17074942<space/></arg><arg name="doi">10.1176/appi.ajp.163.11.1905<space/></arg><arg name="url"></arg><arg name="display-authors">etal</arg></template></extension></listitem></list><paragraph>There were no statistical or meaningful clinical differences in remission rates, response rates, or times to remission or response among any of the medications compared in this study.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR<space/></arg><arg name="title"><space/>The STAR*D Project results: A comprehensive review of findings<space/></arg><arg name="journal"><space/>Current Psychiatry Teports<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>449–59<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>18221624<space/></arg><arg name="doi"><space/>10.1007/s11920-007-0061-3<space/></arg></template></extension><space/>These included bupropion sustained release, bupropion, citalopram, lithium, mirtazapine, nortriptyline, sertraline, triiodothyronine, tranylcypromine, and venlafaxine extended release.<template><target>medical citation needed</target><arg name="date">March 2013</arg></template></paragraph><paragraph>A 2008 review of<space/><link><target>randomized controlled trial</target><trail>s</trail></link><space/>concluded that symptomatic improvement with SSRIs was greatest by the end of the first week of use, but that some improvement continued for at least 6 weeks.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z<space/></arg><arg name="title"><space/>Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action: Systematic Review and Meta-analysis<space/></arg><arg name="journal"><space/>Archives of General Psychiatry<space/></arg><arg name="volume"><space/>63<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1217–23<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>17088502<space/></arg><arg name="pmc"><space/>2211759<space/></arg><arg name="doi"><space/>10.1001/archpsyc.63.11.1217<space/></arg></template></extension></paragraph><heading level='4'>Limitations and strategies</heading><paragraph>Between 30% and 50% of individuals treated with a given antidepressant do not show a response.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Baghai TC, Möller HJ, Rupprecht R<space/></arg><arg name="title"><space/>Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression<space/></arg><arg name="journal"><space/>Current Pharmaceutical Design<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>503–15<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16472142<space/></arg><arg name="doi"><space/>10.2174/138161206775474422<space/></arg></template></extension><extension extension_name='ref' name="SSRIswitch"><template><target>cite journal</target><arg name="author"><space/>Ruhé HG, Huyser J, Swinkels JA, Schene AH<space/></arg><arg name="title"><space/>Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder<space/></arg><arg name="journal"><space/>The Journal of Clinical Psychiatry<space/></arg><arg name="volume"><space/>67<space/></arg><arg name="issue"><space/>12<space/></arg><arg name="pages"><space/>1836–55<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>17194261<space/></arg><arg name="doi"><space/>10.4088/JCP.v67n1203<space/></arg></template></extension><space/>In clinical studies, approximately one-third of patients achieve a full<space/><link><target>remission (medicine)</target><part>remission</part></link>, one-third experience a response and one-third are nonresponders. Partial remission is characterized by the presence of poorly defined residual symptoms. These symptoms typically include depressed mood, psychic anxiety, sleep disturbance, fatigue and diminished interest or pleasure. It is currently unclear which factors predict partial remission. However, it is clear that residual symptoms are powerful predictors of relapse, with relapse rates 36&amp;nbsp;times higher in patients with residual symptoms than in those who experience full remission.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Tranter R, O'Donovan C, Chandarana P, Kennedy S<space/></arg><arg name="title"><space/>Prevalence and outcome of partial remission in depression<space/></arg><arg name="journal"><space/>Journal of Psychiatry & Neuroscience<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>241–7<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12174733<space/></arg><arg name="pmc"><space/>161658<space/></arg></template></extension><space/>In addition, antidepressant drugs tend to lose efficacy over the course of treatment.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Byrne SE, Rothschild AJ<space/></arg><arg name="title"><space/>Loss of Antidepressant Efficacy During Maintenance Therapy<space/></arg><arg name="journal"><space/>The Journal of Clinical Psychiatry<space/></arg><arg name="volume"><space/>59<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>279–88<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="pmid"><space/>9671339<space/></arg><arg name="doi"><space/>10.4088/JCP.v59n0602<space/></arg></template></extension><space/>A number of strategies are used in clinical practice to try to overcome these limits and variations.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Mischoulon D, Nierenberg AA, Kizilbash L, Rosenbaum JF, Fava M<space/></arg><arg name="title"><space/>Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: A survey of clinicians<space/></arg><arg name="journal"><space/>Canadian Journal of Psychiatry<space/></arg><arg name="volume"><space/>45<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>476–81<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="pmid"><space/>10900529<space/></arg></template></extension><space/>They include switching medication, augmentation, and combination.</paragraph><heading level='4'>&quot;Trial and error&quot; switching</heading><paragraph>The<space/><link><target>American Psychiatric Association</target></link><space/>2000 Practice Guideline advises that where no response is achieved following six to eight weeks of treatment with an antidepressant, to switch to an antidepressant in the same class, then to a different class of antidepressant.A 2006 meta-analysis review found wide variation in the findings of prior studies; for patients who had failed to respond to an SSRI antidepressant, between 12% and 86% showed a response to a new drug. However, the more antidepressants an individual had already tried, the less likely they were to benefit from a new antidepressant trial.<extension extension_name='ref' name="SSRIswitch"></extension><space/>However, a later meta-analysis found no difference between switching to a new drug and staying on the old medication; although 34% of treatment resistant patients responded when switched to the new drug, 40% responded without being switched.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Bschor T, Baethge C<space/></arg><arg name="title"><space/>No evidence for switching the antidepressant: Systematic review and meta-analysis of RCTs of a common therapeutic strategy<space/></arg><arg name="journal"><space/>Acta Psychiatrica Scandinavica<space/></arg><arg name="volume"><space/>121<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>174–9<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>19703121<space/></arg><arg name="doi"><space/>10.1111/j.1600-0447.2009.01458.x<space/></arg></template></extension></paragraph><heading level='4'>Augmentation and combination</heading><paragraph>For a partial response, the American Psychiatric Association guidelines suggest augmentation, or adding a drug from a different class. These include:<space/><link><target>Lithium (medication)</target><part>lithium</part></link><space/>and<space/><link><target>thyroid</target></link><space/>augmentation,<space/><link><target>dopamine agonists</target></link>,<space/><link><target>sex steroids</target></link>,<space/><link><target>Norepinephrine reuptake inhibitor</target><part>NRIs</part></link>,<space/><link><target>glucocorticoid</target></link>-specific agents, or the newer<space/><link><target>anticonvulsant</target><trail>s</trail></link>.<extension extension_name='ref' name="augment"><template><target>cite journal</target><arg name="author"><space/>DeBattista C, Lembke A<space/></arg><arg name="title"><space/>Update on augmentation of antidepressant response in resistant depression<space/></arg><arg name="journal"><space/>Current Psychiatry Reports<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>435–40<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>16318821<space/></arg><arg name="doi"><space/>10.1007/s11920-005-0064-x<space/></arg></template></extension></paragraph><paragraph>A combination strategy involves adding another antidepressant, usually from a different class so as to have effect on other mechanisms. Although this may be used in clinical practice, there is little evidence for the relative efficacy or adverse effects of this strategy.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lam RW, Wan DD, Cohen NL, Kennedy SH<space/></arg><arg name="title"><space/>Combining Antidepressants for Treatment-Resistant Depression<space/></arg><arg name="journal"><space/>The Journal of Clinical Psychiatry<space/></arg><arg name="volume"><space/>63<space/></arg><arg name="issue"><space/>8<space/></arg><arg name="pages"><space/>685–93<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12197448<space/></arg><arg name="doi"><space/>10.4088/JCP.v63n0805<space/></arg></template></extension><space/>Other tests recently conducted include the use of<space/><link><target>psychostimulant</target><trail>s</trail></link><space/>as an augmentation therapy. Several studies have shown the efficacy of combining<space/><link><target>modafinil</target></link><space/>to treatment-resistant patients. It has been used to help combat SSRI associated fatigue.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH<space/></arg><arg name="title">Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials<space/></arg><arg name="journal"><space/>The Journal of Clinical Psychiatry<space/></arg><arg name="volume"><space/>74<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1101–7</arg><arg name="year"><space/>2013<space/></arg><arg name="pmid"><space/>24330897<space/></arg><arg name="doi"><space/>10.4088/JCP.13r08560<space/></arg></template></extension></paragraph><heading level='4'>Long-term use</heading><paragraph>The therapeutic effects of antidepressants typically do not continue once the course of medication ends, resulting in a high rate of<space/><link><target>relapse</target></link>. A recent<space/><link><target>meta-analysis</target></link><space/>of 31 placebo-controlled antidepressant trials, mostly limited to studies covering a period of one year, found that 18% of patients who had responded to an antidepressant relapsed while still taking it, compared to 41% whose antidepressant was switched for a<space/><link><target>placebo</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM<space/></arg><arg name="title"><space/>Relapse prevention with antidepressant drug treatment in depressive disorders: A systematic review<space/></arg><arg name="journal"><space/>The Lancet<space/></arg><arg name="volume"><space/>361<space/></arg><arg name="issue"><space/>9358<space/></arg><arg name="pages"><space/>653–61<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12606176<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(03)12599-8<space/></arg></template></extension></paragraph><paragraph>A gradual loss of therapeutic benefit occurs in a minority of people during the course of treatment.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Targum SD<space/></arg><arg name="title">Identification and treatment of antidepressant tachyphylaxis<space/></arg><arg name="journal">Innov Clin Neurosci<space/></arg><arg name="volume">11<space/></arg><arg name="issue">3–4<space/></arg><arg name="pages">24–8<space/></arg><arg name="date">March 2014<space/></arg><arg name="pmid">24800130<space/></arg><arg name="pmc">4008298<space/></arg><arg name="doi"><space/></arg><arg name="url"></arg></template></extension><extension extension_name='ref' name="fava"><template><target>cite journal</target><arg name="author"><space/>Fava GA, Offidani E<space/></arg><arg name="title"><space/>The mechanisms of tolerance in antidepressant action<space/></arg><arg name="journal"><space/>Progress in Neuro-Psychopharmacology and Biological Psychiatry<space/></arg><arg name="volume"><space/>35<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>1593–602<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="pmid"><space/>20728491<space/></arg><arg name="doi"><space/>10.1016/j.pnpbp.2010.07.026<space/></arg></template></extension><space/>A strategy involving the use of pharmacotherapy in the treatment of the acute episode, followed by psychotherapy in its residual phase, has been suggested by some studies.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fava GA, Park SK, Sonino N<space/></arg><arg name="title"><space/>Treatment of recurrent depression<space/></arg><arg name="journal"><space/>Expert Review of Neurotherapeutics<space/></arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1735–40<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>17144786<space/></arg><arg name="doi"><space/>10.1586/14737175.6.11.1735<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Petersen TJ<space/></arg><arg name="title"><space/>Enhancing the efficacy of antidepressants with psychotherapy<space/></arg><arg name="journal"><space/>Journal of Psychopharmacology<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>3 suppl<space/></arg><arg name="pages"><space/>19–28<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16644768<space/></arg><arg name="doi"><space/>10.1177/1359786806064314<space/></arg></template></extension></paragraph><heading level='4'>Comparative efficacy and tolerability</heading><paragraph><template><target>clear</target></template><xhtml:div style="width:100%;" class="NavFrame"><paragraph><xhtml:div class="NavHead" style="background:#fffaf0; text-align:center; font-size:larger;">Comparative efficacy and tolerability table</xhtml:div><xhtml:div class="NavContent" style="text-align:left;display:none;"><table class="wikitable"><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="GG"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="editor1-last">Brunton<space/></arg><arg name="editor1-first">Laurence L.<space/></arg><arg name="editor2-last">Chabner<space/></arg><arg name="editor2-first">Bruce<space/></arg><arg name="editor3-last">Knollmann<space/></arg><arg name="editor3-first">Björn C.<space/></arg><arg name="title">[[Goodman and Gilman's The Pharmacological Basis of Therapeutics]]<space/></arg><arg name="year"><space/>2011<space/></arg><arg name="publisher"><space/>McGraw-Hill Professional<space/></arg><arg name="isbn"><space/>978-0-07-162442-8<space/></arg><arg name="edition"><space/>12th<space/></arg><arg name="location"><space/>New York<space/></arg></template></extension><extension extension_name='ref' name="UpToDate"><template><target>cite web</target><arg name="title">Side effects of antidepressant medications<space/></arg><arg name="work">UpToDate<space/></arg><arg name="publisher">Wolters Kluwer Health<space/></arg><arg name="accessdate">24 October 2013<space/></arg><arg name="url">http://www.uptodate.com/contents/image?imageKey</arg><arg name="archiveurl">http://web.archive.org/web/20131102183135/http://www.uptodate.com/contents/image?imageKey</arg><arg name="archivedate">2 November 2013<space/></arg></template></extension><extension extension_name='ref' name="Martindale"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="title">MARTINDALE – The Complete Drug Reference<space/></arg><arg name="publisher">Pharmaceutical Press<space/></arg><arg name="author">Royal Pharmaceutical Society of Great Britain<space/></arg><arg name="accessdate">31 October 2013<space/></arg><arg name="url">https://www.medicinescomplete.com/mc/martindale/current/login.htm?uri</arg><arg name="archiveurl">http://www.webcitation.org/6IOEuW8Pn<space/></arg><arg name="archivedate">26 July 2013<space/></arg></template></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"><template><target>cite journal</target><arg name="author"><space/>Ernst E; Rand JI; Barnes J; Stevinson C<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="title"><space/>Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.)<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>European Journal of Clinical Pharmacology<space/></arg><arg name="volume"><space/>54<space/></arg><arg name="issue"><space/>8</arg><arg name="pages"><space/>589–94<space/></arg><arg name="doi"><space/>10.1007/s002280050519<space/></arg><arg name="pmid"><space/>9860144<space/></arg><arg name="quote"><space/>Collectively, the data suggest that hypericum is well tolerated, with an incidence of adverse reactions similar to that of placebo.</arg></template></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="Lancet"><template><target>cite journal</target><arg name="author"><space/>Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C<space/></arg><arg name="title"><space/>Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis<space/></arg><arg name="journal"><space/>Lancet<space/></arg><arg name="volume"><space/>373<space/></arg><arg name="issue"><space/>9665<space/></arg><arg name="pages"><space/>746–58<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19185342<space/></arg><arg name="doi"><space/>10.1016/S0140-6736(09)60046-5<space/></arg></template></extension></tablecell><tablecell><space/><extension extension_name='ref' name="GG"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension><xhtml:br></xhtml:br><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="Lancet"></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension><extension extension_name='ref' name="Overdoses"><template><target>cite journal</target><arg name="author"><space/>White N, Litovitz T, Clancy C<space/></arg><arg name="title"><space/>Suicidal antidepressant overdoses: a comparative analysis by antidepressant type<space/></arg><arg name="journal"><space/>J Med Toxicol<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>238–50<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>19031375<space/></arg><arg name="pmc"><space/>3550116<space/></arg><arg name="doi"><space/>10.1007/BF03161207<space/></arg></template></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1"><space/>Taylor<space/></arg><arg name="first1"><space/>D<space/></arg><arg name="title"><space/>The Maudsley prescribing guidelines in psychiatry<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="url"><space/></arg><arg name="isbn"><space/>978-0-470-97948-8<space/></arg><arg name="author2"><space/>Paton, C; Shitij, K<space/></arg><arg name="location"><space/>West Sussex<space/></arg><arg name="publisher"><space/>Wiley-Blackwell<space/></arg></template></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension><extension extension_name='ref' name="AMH"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="title"><space/>Australian Medicines Handbook<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="publisher"><space/>The Australian Medicines Handbook Unit Trust<space/></arg><arg name="isbn"><space/>978-0-9805790-9-3<space/></arg><arg name="edition"><space/>2013<space/></arg><arg name="place"><space/>Adelaide<space/></arg><arg name="editor"><space/>Rossi, S<space/></arg></template></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension><extension extension_name='ref' name="AMH"></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension></tablecell><tablecell><space/><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension><xhtml:br></xhtml:br><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="AMH"></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension></tablecell><tablecell><space/><extension extension_name='ref' name="SJW Cochrane review"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="SJW adverse effects 1998 Review"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension></tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big><link><target>Tricyclic antidepressant</target><trail>s</trail></link><space/>(TCAs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Amitriptyline</target></link></tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>4</tablecell><tablecell><space/>3</tablecell><tablecell><space/>4</tablecell><tablecell><space/>v</tablecell><tablecell><space/>4</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4/3</tablecell></tablerow><tablerow><tablecell><link><target>Amoxapine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>4</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>ND</tablecell></tablerow><tablerow><tablecell><link><target>Clomipramine</target></link></tablecell><tablecell><space/>3</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>4/3</tablecell><tablecell><space/>v</tablecell><tablecell><space/>4</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell></tablerow><tablerow><tablecell><link><target>Desipramine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>ND</tablecell></tablerow><tablerow><tablecell><link><target>Dosulepin</target></link><space/>(Dothiepin)</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell><tablecell><space/>?</tablecell><tablecell><space/>3/2</tablecell><tablecell><space/>3/2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>3/2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>3/2</tablecell></tablerow><tablerow><tablecell><link><target>Doxepin</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>3</tablecell><tablecell><space/>4</tablecell><tablecell><space/>3</tablecell><tablecell><space/>v</tablecell><tablecell><space/>3</tablecell><tablecell><space/>3</tablecell><tablecell><space/>v</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Imipramine</target></link></tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>4</tablecell><tablecell><space/>4/3</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Lofepramine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell></tablerow><tablerow><tablecell><link><target>Maprotiline</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>4</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>v</tablecell><tablecell><space/>ND</tablecell></tablerow><tablerow><tablecell><link><target>Nortriptyline</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>ND</tablecell></tablerow><tablerow><tablecell><link><target>Protriptyline</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4/3</tablecell></tablerow><tablerow><tablecell><link><target>Tianeptine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>4</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell><tablecell><space/>?</tablecell></tablerow><tablerow><tablecell><link><target>Trimipramine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>4</tablecell><tablecell><space/>3</tablecell><tablecell><space/>4</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big><link><target>Monoamine oxidase inhibitors</target></link><space/>(MAOIs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Isocarboxazid</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell></tablerow><tablerow><tablecell><link><target>Moclobemide</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>?</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1/v</tablecell></tablerow><tablerow><tablecell><link><target>Phenelzine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell></tablerow><tablerow><tablecell><link><target>Seligiline</target></link></tablecell><tablecell><space/>?</tablecell><tablecell><space/>3</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell></tablerow><tablerow><tablecell><link><target>Tranylcypromine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big><link><target>Selective serotonin reuptake inhibitors</target></link><space/>(SSRIs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Citalopram</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Escitalopram</target></link></tablecell><tablecell><space/>3</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Fluoxetine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Fluvoxamine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Paroxetine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell></tablerow><tablerow><tablecell><link><target>Sertraline</target></link></tablecell><tablecell><space/>3</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big><link><target>Serotonin-norepinephrine reuptake inhibitors</target></link><space/>(SNRIs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Desvenlafaxine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3/2</tablecell><tablecell><space/>1/2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Duloxetine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell><link><target>Milnacipran</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>?</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell></tablerow><tablerow><tablecell><link><target>Venlafaxine</target></link></tablecell><tablecell><space/>3</tablecell><tablecell><space/>2</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2 (IR)<xhtml:br></xhtml:br>1 (XR)</tablecell><tablecell><space/>3</tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big><link><target>Noradrenergic and specific serotonergic antidepressants</target></link><space/>(NaSSAs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Mianserin</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>?</tablecell><tablecell><space/>4</tablecell><tablecell><space/>v</tablecell><tablecell><space/>4</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell></tablerow><tablerow><tablecell><link><target>Mirtazapine</target></link></tablecell><tablecell><space/>3</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>4</tablecell><tablecell><space/>v</tablecell><tablecell><space/>4</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big><link><target>Serotonin antagonist and reuptake inhibitor</target><trail>s</trail></link><space/>(SARIs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Nefazodone</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell></tablerow><tablerow><tablecell><link><target>Trazodone</target></link></tablecell><tablecell><space/>2<space/><extension extension_name='ref' name="pmid7622801"><template><target>cite journal</target><arg name="author"><space/>van Moffaert M, de Wilde J, Vereecken A, Dierick M, Evrard JL, Wilmotte J, Mendlewicz J<space/></arg><arg name="title"><space/>Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression<space/></arg><arg name="journal"><space/>Int Clin Psychopharmacol<space/></arg><arg name="volume"><space/>10<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>3–9<space/></arg><arg name="date"><space/>March 1995<space/></arg><arg name="pmid"><space/>7622801<space/></arg><arg name="doi"><space/>10.1097/00004850-199503000-00001<space/></arg></template></extension></tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>4</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big>Serotonin modulator and stimulators (SMSs)</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Vilazodone</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3/2</tablecell><tablecell><space/>?</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>4</tablecell><tablecell><space/>2</tablecell></tablerow><tablerow><tablecell><link><target>Vortioxetine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>?</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell></tablerow><tablerow><tablecell colspan="12" style="text-align:center;"><bold><xhtml:big>Other</xhtml:big></bold></tablecell></tablerow><tablerow><tablehead>Drug</tablehead><tablehead>Relative efficacy</tablehead><tablehead>Tolerability</tablehead><tablehead>Danger<xhtml:br></xhtml:br>in overdose</tablehead><tablehead>Weight gain</tablehead><tablehead><link><target>Orthostatic hypotension</target><part>Ortho hypot</part></link></tablehead><tablehead>Inactivating effects</tablehead><tablehead>Activating effects</tablehead><tablehead><link><target>Anticholinergic</target><part>Anti-ACh</part></link></tablehead><tablehead><link><target>QT interval</target><part>QTc i. p.</part></link></tablehead><tablehead>GI<xhtml:br></xhtml:br>toxicity</tablehead><tablehead>SD</tablehead></tablerow><tablerow><tablecell><link><target>Agomelatine</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1/v</tablecell></tablerow><tablerow><tablecell><link><target>Bupropion</target></link></tablecell><tablecell><space/>2</tablecell><tablecell><space/>3</tablecell><tablecell><space/>3/2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2/1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell></tablerow><tablerow><tablecell><link><target>Reboxetine</target></link></tablecell><tablecell><space/>1</tablecell><tablecell><space/>3</tablecell><tablecell><space/>1</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>2</tablecell><tablecell><space/>v</tablecell><tablecell><space/>v</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1</tablecell></tablerow><tablerow><tablecell><link><target>St John's wort</target></link></tablecell><tablecell><space/>3/2</tablecell><tablecell><space/>4</tablecell><tablecell><space/>1</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1/v</tablecell><tablecell><space/>1/v</tablecell></tablerow></table><paragraph><bold>Where:</bold></paragraph><paragraph><italics>For adverse effects/overdose toxicity</italics></paragraph><paragraph>4 means very strong effect/extreme toxicity.</paragraph><paragraph>3 strong effect; efficacious/high toxicity.</paragraph><paragraph>2 moderate effect/moderately toxic.</paragraph><paragraph>1 weak effect/weakly toxic.</paragraph><paragraph>v very weak/negligible effect</paragraph><paragraph><italics>For tolerability</italics></paragraph><paragraph>4 extremely tolerable. These drugs have proven to be better tolerated than the SSRIs.</paragraph><paragraph>3 very tolerable ? few, mild and transient side effects. These are drugs such as the<space/><link><target>Selective serotonin reuptake inhibitors</target><part>SSRIs</part></link>.</paragraph><paragraph>2 moderately tolerable. Some of the more tolerable of TCAs.</paragraph><paragraph>1 poor tolerability. TCAs and MAOIs mostly.</paragraph><paragraph><italics>For efficacy</italics></paragraph><paragraph>3 Superior efficacy drug, according to at least one review article.</paragraph><paragraph>2 Ordinary efficacy drug. Maybe some primary sources indicate superior efficacy relative to superior efficacy agents (e.g. agomelatine has shown superior efficacy to venlafaxine in one clinical trial) but insufficient data to say with much confidence.</paragraph><paragraph>1 Inferior efficacy compared to ordinary efficacy drugs, according to at least one review article.</paragraph><paragraph><bold>Acronyms/terms used in the above table:</bold></paragraph><paragraph>Activating effects adverse effects such as agitation, anxiety, insomnia and tremor.</paragraph><paragraph>AMH Australian Medicines Handbook.<extension extension_name='ref' name="AMH"></extension></paragraph><paragraph>GI Gastrointestinal.</paragraph><paragraph>Inactivating effects sedating effects such as drowsiness, somnolence and sedation.</paragraph><paragraph>IR Immediate release tablets.</paragraph><paragraph>ND No data.</paragraph><paragraph>Ortho hypot<space/><link><target>Orthostatic hypotension</target></link></paragraph><paragraph>QTc i. p.<space/><link><target>QT interval</target><part>QTc interval</part></link><space/>prolongation</paragraph><paragraph>SD Sexual dysfunction.</paragraph><paragraph>XR Extended release tablets.</paragraph><paragraph><bold>PER DRUG NOTES:</bold><space/><extension extension_name='ref' name="GG"></extension><extension extension_name='ref' name="UpToDate"></extension><extension extension_name='ref' name="Martindale"></extension><extension extension_name='ref' name="Lancet"></extension><extension extension_name='ref' name="isbn 9780470979488"></extension><extension extension_name='ref' name="Overdoses"></extension><extension extension_name='ref' name="AMH"></extension></paragraph><paragraph><bold><link><target>Tricyclic antidepressant</target><trail>s</trail></link><space/>(TCAs)</bold></paragraph><paragraph><link><target>Amitriptyline</target></link>:Preferentially (8x over norepinephrine) inhibits the reuptake of serotonin but norepinephrine reuptake inhibition is clinically significant.<extension extension_name='ref' name="GG"></extension><space/>Listed as a more hepatotoxic antidepressant in a recent review article.<extension extension_name='ref' name="Hep"><template><target>cite journal</target><arg name="last1">Voican</arg><arg name="first1">CS</arg><arg name="last2">Corruble</arg><arg name="first2">E</arg><arg name="last3">Naveau</arg><arg name="first3">S</arg><arg name="last4">Perlemuter</arg><arg name="first4">G</arg><arg name="title">Antidepressant-induced liver injury: a review for clinicians.</arg><arg name="journal">The American Journal of Psychiatry</arg><arg name="date">April 2014</arg><arg name="volume">171</arg><arg name="issue">4</arg><arg name="pages">404–15</arg><arg name="doi">10.1176/appi.ajp.2013.13050709</arg><arg name="pmid">24362450</arg></template></extension></paragraph><paragraph><link><target>Amoxapine</target></link>:Sometimes classed with the tetracyclic antidepressants. Has<space/><link><target>atypical antipsychotic</target></link><space/>actions too. Not available in Australia, Canada or the UK but available in the US. May be faster acting. Antidopaminergic, which means that it can cause<space/><link><target>extrapyramidal side effects</target></link>,<space/><link><target>tardive dyskinesia</target></link><space/>and<space/><link><target>neuroleptic malignant syndrome</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="title">AMOXAPINE tablet [Watson Laboratories, Inc.]<space/></arg><arg name="work">DailyMed<space/></arg><arg name="publisher">Watson Laboratories, Inc.<space/></arg><arg name="date">August 2010<space/></arg><arg name="accessdate">30 October 2013<space/></arg><arg name="url">http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid</arg><arg name="archiveurl">http://web.archive.org/web/20131102093757/http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid</arg><arg name="archivedate">2 November 2013<space/></arg></template></extension><space/>Causes kidney failure and seizures in overdose, although it usually does not cause cardiotoxic effects in overdose.<extension extension_name='ref' name="CPT"></extension></paragraph><paragraph><link><target>Clomipramine</target></link>:Highly selective (~120x) for serotonin reuptake inhibition. More epileptogenic than other TCAs.<extension extension_name='ref' name="GG"></extension></paragraph><paragraph><link><target>Desipramine</target></link>:Preferentially inhibits the reuptake of norepinephrine (22x over serotonin).<extension extension_name='ref' name="GG"></extension></paragraph><paragraph><link><target>Dosulepin</target></link><space/>(Dothiepin):Not available in the US. Available in Australia (where it is still commonly referred to as dothiepin) and the UK.<xhtml:br></xhtml:br>Weight gain: probably 2<xhtml:br></xhtml:br>Danger in overdose: 4<space/><extension extension_name='ref' name="AMH"></extension></paragraph><paragraph><link><target>Doxepin</target></link>:Somewhat selective for inhibiting norepinephrine reuptake (2.3x over serotonin).</paragraph><paragraph><link><target>Imipramine</target></link>:First marketed<space/><link><target>Tricyclic antidepressant</target><part>TCA</part></link>. Somewhat selective for serotonin reuptake (26x over norepinephrine).<xhtml:br></xhtml:br>Relative efficacy: 3<extension extension_name='ref' name="pmid8912401"><template><target>cite journal</target><arg name="author"><space/>Bruijn JA, Moleman P, Mulder PG, van den Broek WW, van Hulst AM, van der Mast RC, van de Wetering BJ<space/></arg><arg name="title"><space/>A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients<space/></arg><arg name="journal"><space/>Psychopharmacology<space/></arg><arg name="volume"><space/>127<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>231–7<space/></arg><arg name="year"><space/>1996<space/></arg><arg name="pmid"><space/>8912401<space/></arg><arg name="doi"><space/>10.1007/BF02246131<space/></arg></template></extension><extension extension_name='ref' name="pmid10463374"><template><target>cite journal</target><arg name="author"><space/>Bruijn JA, Moleman P, Mulder PG, van den Broek WW<space/></arg><arg name="title"><space/>Depressed in-patients respond differently to imipramine and mirtazapine<space/></arg><arg name="journal"><space/>Pharmacopsychiatry<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>87–92<space/></arg><arg name="year"><space/>1999<space/></arg><arg name="pmid"><space/>10463374<space/></arg><arg name="doi"><space/>10.1055/s-2007-979200<space/></arg></template></extension><space/>More hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Lofepramine</target></link>:Not licensed in Australia, US or Canada. Licensed in the UK and other European countries.<xhtml:br></xhtml:br><link><target>QT interval</target><part>QTc i. p.</part></link>: 1 (dose-dependent)</paragraph><paragraph><link><target>Maprotiline</target></link>:Fairly selective (~90x over dopamine) norepinephrine reuptake inhibitor.<extension extension_name='ref' name="GG"></extension></paragraph><paragraph><link><target>Nortriptyline</target></link>:Active metabolite of amitriptyline. Somewhat selective (4.2x) for norepinephrine reuptake inhibition.</paragraph><paragraph><link><target>Protriptyline</target></link>:Relatively (14x over serotonin) selective norepinephrine reuptake inhibition.</paragraph><paragraph><link><target>Tianeptine</target></link>:Enhances the reuptake of serotonin and increases dopaminergic and glutamatergic neurotransmission. Not approved for clinical use in Australia, Canada, the UK, the US and Ireland. More hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Trimipramine</target></link>:Has antidopaminergic effects and hence can cause extrapyramidal side effects,<space/><link><target>tardive dyskinesia</target></link><space/>and<space/><link><target>neuroleptic malignant syndrome</target></link>.</paragraph><paragraph><bold><link><target>Monoamine oxidase inhibitors</target></link><space/>(MAOIs)</bold></paragraph><paragraph><link><target>Isocarboxazid</target></link>:Not licensed for use in Australia.</paragraph><paragraph><link><target>Moclobemide</target></link>:Only clinically utilized<space/><link><target>reversible inhibitor of monoamine oxidase A</target></link><space/>(RIMA). Not approved for use in the US. Approved for clinical use in Australia, Canada, most European countries (including the Czech Republic, Finland and Ireland), New Zealand, Singapore, South Africa and the UK.<xhtml:br></xhtml:br>Activating effects: ? (insomnia common according to the AMH)</paragraph><paragraph><link><target>Phenelzine</target></link>:Phenelzine is more prone than tranylcypromine and most other antidepressant to causing liver damage.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Seligiline</target></link>:Originally used a treatment for Parkinson's disease due to its selective, irreversible inhibition of<space/><link><target>MAO-B</target></link><space/>but at higher doses<space/><link><target>MAO-A</target></link><space/>inhibition occurs.</paragraph><paragraph><link><target>Tranylcypromine</target></link>:Metabolized into amphetamine analogues<space/><italics>in vivo</italics>. Can cause liver damage.<extension extension_name='ref' name="AMH"></extension></paragraph><paragraph><bold><link><target>Selective serotonin reuptake inhibitors</target></link><space/>(SSRIs)</bold></paragraph><paragraph><link><target>Citalopram</target></link>:Most likely of the SSRIs to prolong the<space/><link><target>QT interval</target></link>. Also the most toxic SSRI in overdose. Less hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension><xhtml:br></xhtml:br><link><target>QT interval</target><part>QTc i. p.</part></link>: 2 (dose dependent; doses &gt;40&amp;nbsp;mg/day are particularly dangerous)</paragraph><paragraph><link><target>Escitalopram</target></link>:The more active S-enantiomer of citalopram. May be the most efficacious of the SSRIs (although no statistically significant difference between the efficacy of sertraline and escitalopram have been teased out to date). Based on the available evidence it is less toxic than its racemic counterpart, (R,S)-citalopram, in overdose. Less hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Fluoxetine</target></link>:First SSRI to receive FDA approval in 1987. Some studies have shown slight (often statistically insignificant) weight reductions in those on fluoxetine. Has the longest net half-life (taking into account the effects of its active metabolite,<space/><link><target>norfluoxetine</target></link>) of any antidepressant clinically used, and consequently, when abruptly stopped, withdrawal effects are usually mild and rare. Dermatologic reactions are more common than with sertraline.<extension extension_name='ref' name="Martindale"></extension></paragraph><paragraph><link><target>Fluvoxamine</target></link>:Not<space/><link><target>Food and Drug Administration</target><part>FDA</part></link><space/>approved for major depression; FDA approved for<space/><link><target>Obsessive-compulsive disorder</target><part>OCD</part></link>. Has the highest affinity of any SSRI towards the<space/><link><target>sigma-1 receptor</target></link><space/>at which it serves as an agonist.<extension extension_name='ref' name="sig"><template><target>cite journal</target><arg name="author"><space/>Fishback JA, Robson MJ, Xu YT, Matsumoto RR<space/></arg><arg name="title"><space/>Sigma receptors: potential targets for a new class of antidepressant drug<space/></arg><arg name="journal"><space/>Pharmacol. Ther.<space/></arg><arg name="volume"><space/>127<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>271–82<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20438757<space/></arg><arg name="pmc"><space/>3993947<space/></arg><arg name="doi"><space/>10.1016/j.pharmthera.2010.04.003<space/></arg></template></extension><extension extension_name='ref' name="psychdep"></extension><space/>Less hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Paroxetine</target></link>:Only SSRI that's not Australian pregnancy category C but is rather category D due to an increased risk of<space/><link><target>Persistent fetal circulation</target><part>Persistent Pulmonary Hypertension of the Newborn</part></link>. The<space/><link><target>Food and Drug Administration</target><part>FDA</part></link><space/>of the US has placed it in category D. It is associated with a higher risk of sexual dysfunction, weight gain, anticholinergic side effects and drowsiness than the other SSRIs. Has a short half life compared to other SSRIs and hence is the most prone to causing withdrawal effects whenever a dose is missed. Paroxetine has the lowest affinity for the sigma-1 receptors of all the SSRIs.<extension extension_name='ref' name="sig"></extension><space/>It also possesses the highest propensity of any SSRI for causing<space/><link><target>extrapyramidal symptoms</target></link>.<extension extension_name='ref' name="CPT"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="title"><space/>Clinical Pharmacy and Therapeutics<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="publisher"><space/>Churchill Livingstone Elsevier<space/></arg><arg name="isbn"><space/>978-0-7020-4293-5<space/></arg><arg name="edition"><space/>4th<space/></arg><arg name="location"><space/>Edinburgh<space/></arg><arg name="origyear"><space/>1994<space/></arg><arg name="editor"><space/>Walker, R; Whittlesea, C<space/></arg></template></extension><space/>Less hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Sertraline</target></link>:Highest risk of psychiatric side effects (e.g. mania, suicidal behavior/ideation, psychosis, etc.)<extension extension_name='ref' name="Martindale"></extension><space/>Has slight (but clinically significant) inhibitory effects on dopamine reuptake.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Borkowska A, Pilaczyńska E, Araszkiewicz A, Rybakowski J<space/></arg><arg name="title"><space/>[The effect of sertraline on cognitive functions in patients with obsessive-compulsive disorder]<space/></arg><arg name="language"><space/>Polish<space/></arg><arg name="journal"><space/>Psychiatr. Pol.<space/></arg><arg name="volume"><space/>36<space/></arg><arg name="issue"><space/>6 Suppl<space/></arg><arg name="pages"><space/>289–95<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12647451<space/></arg><arg name="doi"></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Schmitt JA, Ramaekers JG, Kruizinga MJ, van Boxtel MP, Vuurman EF, Riedel WJ<space/></arg><arg name="title"><space/>Additional dopamine reuptake inhibition attenuates vigilance impairment induced by serotonin reuptake inhibition in man<space/></arg><arg name="journal"><space/>J. Psychopharmacol.<space/></arg><arg name="volume"><space/>16<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>207–14<space/></arg><arg name="year"><space/>2002<space/></arg><arg name="pmid"><space/>12236626<space/></arg><arg name="doi"><space/>10.1177/026988110201600303<space/></arg></template></extension><space/>Has the second highest affinity of the SSRIs towards the sigma-1 receptor where it may serve as a sigma-1 receptor antagonist.<extension extension_name='ref' name="psychdep"><template><target>cite journal</target><arg name="author"><space/>Kishimoto A, Todani A, Miura J, Kitagaki T, Hashimoto K<space/></arg><arg name="title"><space/>The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report<space/></arg><arg name="journal"><space/>Ann Gen Psychiatry<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>23<space/></arg><arg name="year"><space/>2010<space/></arg><arg name="pmid"><space/>20492642<space/></arg><arg name="pmc"><space/>2881105<space/></arg><arg name="doi"><space/>10.1186/1744-859X-9-23<space/></arg></template></extension><xhtml:br></xhtml:br>GI toxicity: 2 (mostly diarrhoea)<extension extension_name='ref' name="isbn 9780470979488"></extension></paragraph><paragraph><bold><link><target>Serotonin-norepinephrine reuptake inhibitors</target></link><space/>(SNRIs)</bold></paragraph><paragraph><link><target>Desvenlafaxine</target></link>:Active metabolite of venlafaxine.</paragraph><paragraph><link><target>Duloxetine</target></link>:Unlike the other SNRIs listed here duloxetine does not cause dose-dependent hypertension as a common adverse effect. Used to relieve neuropathic pain too. More hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Milnacipran</target></link>:Primarily used as a treatment for<space/><link><target>neuropathic pain</target></link>.<xhtml:br></xhtml:br>Danger in overdose: ? (No single-drug fatal overdoses reported yet)</paragraph><paragraph><link><target>Venlafaxine</target></link>:Relatively selective (116x) for serotonin reuptake inhibition over norepinephrine.<xhtml:br></xhtml:br>GI toxicity: 2 (IR) / 1 (XR)</paragraph><paragraph><bold><link><target>Noradrenergic and specific serotonergic antidepressants</target></link><space/>(NaSSAs)</bold></paragraph><paragraph><link><target>Mianserin</target></link>:Not licensed for use in the US and Canada. Licensed for use in Australia and the UK. Can cause blood dyscrasias (including<space/><link><target>agranulocytosis</target></link>) and consequently both the<space/><link><target>British National Formulary</target><part>BNF</part></link><space/>and<space/><link><target>Australian Medicines Handbook</target><part>AMH</part></link><space/>recommend regular complete blood count monitoring.<extension extension_name='ref' name="AMH"></extension><extension extension_name='ref' name="BNF"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1"><space/>Joint Formulary Committee<space/></arg><arg name="title"><space/>British National Formulary (BNF)<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="isbn"><space/>978-0-85711-084-8<space/></arg><arg name="edition"><space/>65<space/></arg><arg name="location"><space/>London, UK<space/></arg><arg name="publisher"><space/>Pharmaceutical Press<space/></arg></template></extension></paragraph><paragraph><link><target>Mirtazapine</target></link>:Licensed for use in the US, UK, Australia and Canada. Mianserin's successor and analogue.</paragraph><paragraph><bold><link><target>Serotonin antagonist and reuptake inhibitor</target><trail>s</trail></link><space/>(SARIs)</bold></paragraph><paragraph><link><target>Nefazodone</target></link>:Risk of<space/><link><target>hepatotoxicity</target></link>. Available in the US but not in Canada, Australia or Europe.</paragraph><paragraph><link><target>Trazodone</target></link>:Not available in Australia. More hepatotoxic than other antidepressants.<extension extension_name='ref' name="Hep"></extension><xhtml:br></xhtml:br>Relative efficacy: 2<space/><extension extension_name='ref' name="pmid7622801"></extension></paragraph><paragraph><bold>Serotonin modulator and stimulators (SMSs)</bold></paragraph><paragraph><link><target>Vilazodone</target></link>:Potential for<space/><link><target>serotonin syndrome</target></link><space/>as an adverse effect.<xhtml:br></xhtml:br>Danger in overdose: ? (probably low aside from an increased risk of serotonin syndrome)</paragraph><paragraph><link><target>Vortioxetine</target></link>:Introduced to the US market in September 2013 and hence data on its adverse effects may be lagging behind.<space/><link><target>Serotonin syndrome</target></link><space/>is a possible (rare) adverse effect.</paragraph><paragraph><bold>Other</bold></paragraph><paragraph><link><target>Agomelatine</target></link>:Not licensed in the US or Canada. Licensed in Australia and the UK.<xhtml:br></xhtml:br>Relative efficacy: 2<space/><extension extension_name='ref' name="pmid19708724"><template><target>cite journal</target><arg name="author"><space/>Goodwin GM<space/></arg><arg name="title"><space/>Clinical studies on the efficacy of agomelatine on depressive symptoms<space/></arg><arg name="journal"><space/>CNS Drugs<space/></arg><arg name="volume"><space/>23 Suppl 2<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>35–9<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19708724<space/></arg><arg name="doi"><space/>10.2165/11318650-000000000-00000<space/></arg></template></extension></paragraph><paragraph><link><target>Bupropion</target></link>:Only licensed in the UK and Australia as a smoking cessation aid, but in the US it is licensed for the treatment of major depressive disorder. More hepatotoxic than most other antidepressants.<extension extension_name='ref' name="Hep"></extension></paragraph><paragraph><link><target>Reboxetine</target></link>:Not licensed in the US or Canada. Licensed in Australia and the UK.</paragraph><paragraph><link><target>St John's wort</target></link>:Not a prescription drug in most countries; available as an<space/><link><target>over-the-counter</target></link><space/>herbal supplement.</paragraph></xhtml:div></paragraph></xhtml:div></paragraph><heading level='3'>Anxiety disorders</heading><heading level='4'>Generalized anxiety disorder</heading><paragraph>Antidepressants are recommended by the National Institute for Health and Care Excellence (NICE) for the treatment of<space/><link><target>generalized anxiety disorder</target></link><space/>(GAD) that has failed to respond to conservative measures such as education and self-help activities. GAD is a common disorder of which the central feature is excessive worry about a number of different events. Key symptoms include excessive anxiety about multiple events and issues, and difficulty controlling worrisome thoughts that persists for at least 6 months.</paragraph><paragraph>Antidepressants provide a modest-to-moderate reduction in anxiety in GAD,<extension extension_name='ref' name="urlwww.nice.org.uk"><template><target>cite web</target><arg name="url">http://www.nice.org.uk/nicemedia/live/13314/52599/52599.pdf<space/></arg><arg name="title">www.nice.org.uk<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate">20 February 2013</arg></template></extension><space/>and are superior to placebo in treating GAD.<extension extension_name='ref' name="Kapczinski"><template><target>cite journal</target><arg name="author"><space/>Kapczinski F, Lima MS, Souza JS, Schmitt R<space/></arg><arg name="title"><space/>Antidepressants for generalized anxiety disorder<space/></arg><arg name="journal"><space/>Cochrane Database Syst Rev<space/></arg><arg name="volume"><space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>CD003592<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12804478<space/></arg><arg name="doi"><space/>10.1002/14651858.CD003592<space/></arg><arg name="url"><space/></arg><arg name="editor1-last"><space/>Kapczinski<space/></arg><arg name="editor1-first"><space/>Flavio FK<space/></arg></template></extension><space/>The efficacy of different antidepressants is similar.<extension extension_name='ref' name="urlwww.nice.org.uk"></extension><extension extension_name='ref' name="Kapczinski"></extension></paragraph><heading level='4'>Obsessive compulsive disorder</heading><paragraph>SSRIs are a second line treatment of adult<space/><link><target>obsessive compulsive disorder</target></link><space/>(OCD) with mild functional impairment and as first line treatment for those with moderate or severe impairment. In children, SSRIs can be considered as a second line therapy in those with moderate-to-severe impairment, with close monitoring for psychiatric adverse effects.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.nice.org.uk/nicemedia/pdf/cg031niceguideline.pdf<space/></arg><arg name="title">www.nice.org.uk<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>SSRIs are efficacious in the treatment of OCD; patients treated with SSRIs are about twice as likely to respond to treatment as those treated with placebo.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Arroll B, Elley CR, Fishman T, Goodyear-Smith FA, Kenealy T, Blashki G, Kerse N, Macgillivray S<space/></arg><arg name="title"><space/>Antidepressants versus placebo for depression in primary care<space/></arg><arg name="journal"><space/>Cochrane Database Syst Rev<space/></arg><arg name="volume"><space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>CD007954<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19588448<space/></arg><arg name="doi"><space/>10.1002/14651858.CD007954<space/></arg><arg name="url"><space/></arg><arg name="editor1-last"><space/>Arroll<space/></arg><arg name="editor1-first"><space/>Bruce<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.medscape.com/viewarticle/570825+<space/></arg><arg name="title">Medscape Log In<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>Efficacy has been demonstrated both in short-term treatment trials of 6 to 24 weeks and in discontinuation trials of 28 to 52 weeks duration.<extension extension_name='ref'><template><target>cite journal</target><arg name="pmid"><space/>22226028</arg><arg name="year"><space/>2012</arg><arg name="author1"><space/>Fineberg</arg><arg name="first1"><space/>N. A.</arg><arg name="title"><space/>Evidence-based pharmacotherapy of obsessive-compulsive disorder</arg><arg name="journal"><space/>The International Journal of Neuropsychopharmacology</arg><arg name="volume"><space/>15</arg><arg name="issue"><space/>8</arg><arg name="pages"><space/>1173–91</arg><arg name="last2"><space/>Brown</arg><arg name="first2"><space/>A</arg><arg name="last3"><space/>Reghunandanan</arg><arg name="first3"><space/>S</arg><arg name="last4"><space/>Pampaloni</arg><arg name="first4"><space/>I</arg><arg name="doi"><space/>10.1017/S1461145711001829</arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">https://www.apotex.com/us/en/products/downloads/pil/paxil_irtb_ins.pdf<space/></arg><arg name="title">Paroxetine prescribing information<space/></arg><arg name="accessdate">30 January 2015<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019839s070,020990s032lbl.pdf<space/></arg><arg name="title">Sertraline prescribing information<space/></arg><arg name="accessdate">30 January 2015<space/></arg></template></extension></paragraph><heading level='3'>Eating disorders</heading><paragraph>Anti-depressants are recommended as an alternative or additional first step to self-help programs in the treatment of<space/><link><target>bulimia nervosa</target></link>.<extension extension_name='ref' name="urlwww.nice.org.uk2"><template><target>cite web</target><arg name="url">http://www.nice.org.uk/nicemedia/pdf/CG9FullGuideline.pdf<space/></arg><arg name="title">www.nice.org.uk<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>SSRIs (fluoxetine in particular) are preferred over other anti-depressants due to their acceptability, tolerability, and superior reduction of symptoms in short term trials. Long term efficacy remains poorly characterized.<space/><link><target>Bupropion</target></link><space/>is not recommended for the treatment of eating disorders due to an increased risk of seizure.<extension extension_name='ref'>http://www.nlm.nih.gov/medlineplus/druginfo/meds/a695033.html</extension></paragraph><paragraph>Similar recommendations apply to<space/><link><target>binge eating disorder</target></link>.<extension extension_name='ref' name="urlwww.nice.org.uk2"></extension><space/>SSRIs provide short term reductions in binge eating behavior, but have not been associated with significant weight loss.<extension extension_name='ref' name="urlNational Guideline Clearinghouse | Practice guideline for the treatment of patients with eating disorders."><template><target>cite web</target><arg name="url">http://www.guidelines.gov/content.aspx?id</arg><arg name="title">National Guideline Clearinghouse &#124; Practice guideline for the treatment of patients with eating disorders<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension></paragraph><paragraph>Clinical trials have generated mostly negative results for the use of SSRI's in the treatment of<space/><link><target>anorexia nervosa</target></link>.<extension extension_name='ref' name="pmid21414249"><template><target>cite journal</target><arg name="author"><space/>Flament MF, Bissada H, Spettigue W<space/></arg><arg name="title"><space/>Evidence-based pharmacotherapy of eating disorders<space/></arg><arg name="journal"><space/>Int. J. Neuropsychopharmacol.<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>189–207<space/></arg><arg name="date"><space/>March 2012<space/></arg><arg name="pmid"><space/>21414249<space/></arg><arg name="doi"><space/>10.1017/S1461145711000381<space/></arg><arg name="url"><space/></arg></template></extension><space/>Treatment guidelines from the National Institute of Health and Care Excellence<extension extension_name='ref' name="urlwww.nice.org.uk2"></extension><space/>recommend against the use of SSRIs in this disorder. Those from the American Psychiatric Association note that SSRIs confer no advantage regarding weight gain, but that they may be used for the treatment of co-existing depressive, anxiety, or obsessive-compulsive disorders.<extension extension_name='ref' name="urlNational Guideline Clearinghouse | Practice guideline for the treatment of patients with eating disorders."></extension></paragraph><heading level='3'>Pain</heading><heading level='4'>Fibromyalgia</heading><paragraph>A 2012 meta analysis concluded that antidepressants treatment favorably affects pain, health-related quality of life, depression, and sleep in<space/><link><target>fibromyalgia</target></link><space/>syndrome. Tricyclics appear to be the most effective class, with moderate effects on pain and sleep and small effects on fatigue and health-related quality of life. The fraction of people experiencing a 30% pain reduction on tricyclics was 48% vs 28% for placebo. For SSRIs and SNRIs the fraction of people experiencing a 30% pain reduction was 36% (20% in the placebo comparator arms) and 42% (32% in the corresponding placebo comparator arms). Discontinuation of treatment due to side effects was common.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C<space/></arg><arg name="title"><space/>The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis<space/></arg><arg name="journal"><space/>CNS Drugs<space/></arg><arg name="volume"><space/>26<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>297–307<space/></arg><arg name="date">April 2012<space/></arg><arg name="pmid"><space/>22452526<space/></arg><arg name="doi"><space/>10.2165/11598970-000000000-00000<space/></arg><arg name="url"><space/></arg></template></extension><space/>Antidepressants including amitriptyline, fluoxetine, duloxetine, milnacipran, moclobemide, and pirlindole are recommended by the European League Against Rheumatism (EULAR) for the treatment of fibromyalgia based on &quot;limited evidence&quot;.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.enfa-europe.eu/assets/downloads/eular.pdf<space/></arg><arg name="title">www.enfa-europe.eu<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension></paragraph><heading level='4'>Neuropathic Pain</heading><paragraph>A 2014 meta analysis from the<space/><link><target>Cochrane Collaboration</target></link><space/>found the antidepressant duloxetine effective for the treatment of pain resulting from diabetic neuropathy.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lunn MP, Hughes RA, Wiffen PJ<space/></arg><arg name="title"><space/>Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia<space/></arg><arg name="journal"><space/>Cochrane Database Syst Rev<space/></arg><arg name="volume"><space/>1<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>CD007115<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>24385423<space/></arg><arg name="doi"><space/>10.1002/14651858.CD007115.pub3<space/></arg><arg name="url"><space/></arg></template></extension><space/>The same group reviewed data for amitryptyline in the treatment of neuropathic pain and found limited useful randomized clinical trial data, but concluded that the long history of successful use in the community for the treatment of fibromyalgia and neuropathic pain justified its continued use.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ<space/></arg><arg name="title"><space/>Amitriptyline for neuropathic pain and fibromyalgia in adults<space/></arg><arg name="journal"><space/>Cochrane Database Syst Rev<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>CD008242<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>23235657<space/></arg><arg name="doi"><space/>10.1002/14651858.CD008242.pub2<space/></arg><arg name="url"><space/></arg></template></extension></paragraph><heading level='2'>Adverse effects</heading><paragraph>Difficulty tolerating<space/><link><target>adverse effects</target></link><space/>is the most common reason for antidepressant discontinuation.<template><target>medical citation needed</target><arg name="date">November 2012</arg></template></paragraph><heading level='3'>General</heading><paragraph><template><target>Main</target><arg>Serotonin syndrome</arg><arg>MAOIs</arg></template>Almost any medication involved with serotonin regulation has the potential to cause<space/><link><target>serotonin syndrome</target><part>serotonin toxicity</part></link><space/>(also known as<space/><italics>serotonin syndrome</italics>)<template><target>spaced ndash</target></template><space/>an excess of serotonin that can induce mania, restlessness, agitation,<space/><link><target>emotional lability</target></link>, insomnia and confusion as its primary symptoms.<extension extension_name='ref' name="pmid12771076"><template><target>cite journal</target><arg name="author"><space/>Birmes P, Coppin D, Schmitt L, Lauque D<space/></arg><arg name="title"><space/>Serotonin syndrome: a brief review<space/></arg><arg name="journal"><space/>CMAJ<space/></arg><arg name="volume"><space/>168<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1439–42<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12771076<space/></arg><arg name="pmc"><space/>155963<space/></arg><arg name="doi"><space/></arg></template></extension><extension extension_name='ref' name="pmid15784664"><template><target>cite journal</target><arg name="author"><space/>Boyer EW, Shannon M<space/></arg><arg name="title"><space/>The serotonin syndrome<space/></arg><arg name="journal"><space/>N. Engl. J. Med.<space/></arg><arg name="volume"><space/>352<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>1112–20<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>15784664<space/></arg><arg name="doi"><space/>10.1056/NEJMra041867<space/></arg><arg name="url"><space/>http://toxicology.ucsd.edu/art%203%20serotonin%20syndrome.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="archiveurl"><space/>http://web.archive.org/web/20130618053344/http://toxicology.ucsd.edu/art%203%20serotonin%20syndrome.pdf<space/></arg><arg name="archivedate"><space/>18 June 2013<space/></arg></template></extension><space/>Although the condition is serious, it is not particularly common, generally only appearing at high doses or while on other medications. Assuming proper medical intervention has been taken (within about 24&amp;nbsp;hours) it is rarely fatal.<extension extension_name='ref' name="pmid10941349"><template><target>cite journal</target><arg name="author"><space/>Mason PJ, Morris VA, Balcezak TJ<space/></arg><arg name="title"><space/>Serotonin syndrome. Presentation of 2 cases and review of the literature<space/></arg><arg name="journal"><space/>Medicine<space/></arg><arg name="volume"><space/>79<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>201–9<space/></arg><arg name="year"><space/>2000<space/></arg><arg name="pmid"><space/>10941349<space/></arg><arg name="doi"><space/>10.1097/00005792-200007000-00001<space/></arg></template></extension><extension extension_name='ref' name="pmid10818648"><template><target>cite journal</target><arg name="author"><space/>Sampson E, Warner JP<space/></arg><arg name="title"><space/>Serotonin syndrome: potentially fatal but difficult to recognize<space/></arg><arg name="journal"><space/>Br J Gen Pract<space/></arg><arg name="volume"><space/>49<space/></arg><arg name="issue"><space/>448<space/></arg><arg name="pages"><space/>867–8<space/></arg><arg name="year"><space/>1999<space/></arg><arg name="pmid"><space/>10818648<space/></arg><arg name="pmc"><space/>1313553<space/></arg><arg name="doi"><space/></arg></template></extension></paragraph><paragraph><link><target>MAOIs</target></link><space/>tend to have pronounced (sometimes fatal) interactions with a wide variety of medications and<space/><link><target>over-the-counter drug</target><trail>s</trail></link>. If taken with foods that contain very high levels of<space/><link><target>tyramine</target></link><space/>(e.g., mature cheese, cured meats, or yeast extracts), they may cause a potentially lethal<space/><link><target>hypertensive crisis</target></link>. At lower doses the person may be bothered by only a headache due to an increase in blood pressure.<extension extension_name='ref' name="pmid19742203"><template><target>cite journal</target><arg name="author"><space/>Sathyanarayana Rao TS, Yeragani VK<space/></arg><arg name="title"><space/>Hypertensive crisis and cheese<space/></arg><arg name="journal"><space/>Indian J Psychiatry<space/></arg><arg name="volume"><space/>51<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>65–6<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19742203<space/></arg><arg name="pmc"><space/>2738414<space/></arg><arg name="doi"><space/>10.4103/0019-5545.44910<space/></arg></template></extension></paragraph><paragraph>In response to these adverse effects, a different type of MAOI has been developed: the<space/><link><target>reversible inhibitor of monoamine oxidase A</target></link><space/>(RIMA) class of drugs. Their primary advantage is that they do not require the person to follow a special diet, while being purportedly effective as SSRIs and tricyclics in treating depressive disorders.<extension extension_name='ref' name="pmid7717091"><template><target>cite journal</target><arg name="author"><space/>Paykel ES<space/></arg><arg name="title"><space/>Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression<space/></arg><arg name="journal"><space/>Acta Psychiatr Scand Suppl<space/></arg><arg name="volume"><space/>386<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>22–7<space/></arg><arg name="year"><space/>1995<space/></arg><arg name="pmid"><space/>7717091<space/></arg><arg name="doi"><space/>10.1111/j.1600-0447.1995.tb05920.x<space/></arg></template></extension></paragraph><heading level='3'>Pregnancy</heading><paragraph>SSRI use in pregnancy has been associated with a variety of risks with varying degrees of proof of causation. As depression is independently associated with negative pregnancy outcomes, determining the extent to which observed associations between antidepressant use and specific adverse outcomes reflects a causative relationship has been difficult in some cases.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Malm H<space/></arg><arg name="title"><space/>Prenatal exposure to selective serotonin reuptake inhibitors and infant outcome<space/></arg><arg name="journal"><space/>Ther Drug Monit<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>607–14<space/></arg><arg name="date">December 2012<space/></arg><arg name="pmid"><space/>23042258<space/></arg><arg name="doi"><space/>10.1097/FTD.0b013e31826d07ea<space/></arg><arg name="url"><space/></arg></template></extension><space/>In other cases, the attribution of adverse outcomes to antidepressant exposure seems fairly clear.</paragraph><paragraph>SSRI use in pregnancy is associated with an increased risk of spontaneous abortion of about 1.7-fold,<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Rahimi R, Nikfar S, Abdollahi M<space/></arg><arg name="title"><space/>Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials<space/></arg><arg name="journal"><space/>Reproductive Toxicology<space/></arg><arg name="volume"><space/>22<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>571–575<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16720091<space/></arg><arg name="doi"><space/>10.1016/j.reprotox.2006.03.019<space/></arg></template></extension><extension extension_name='ref' name="Nikfar S, Rahimi R, Hendoiee N, Abdollahi M 2012 75"><template><target>cite journal</target><arg name="author"><space/>Nikfar S, Rahimi R, Hendoiee N, Abdollahi M<space/></arg><arg name="title"><space/>Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis<space/></arg><arg name="journal"><space/>Daru<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>75<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>23351929<space/></arg><arg name="pmc"><space/>3556001<space/></arg><arg name="doi"><space/>10.1186/2008-2231-20-75<space/></arg><arg name="url"><space/></arg></template></extension><space/>and is associated with preterm birth and low birth weight.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Huang H, Coleman S, Bridge JA, Yonkers K, Katon W<space/></arg><arg name="title"><space/>A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight<space/></arg><arg name="journal"><space/>General Hospital Psychiatry<space/></arg><arg name="volume"><space/>36<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>13–8<space/></arg><arg name="year"><space/>2014<space/></arg><arg name="pmid"><space/>24094568<space/></arg><arg name="pmc"><space/>3877723<space/></arg><arg name="doi"><space/>10.1016/j.genhosppsych.2013.08.002<space/></arg></template></extension></paragraph><paragraph>A systematic review of the risk of major birth defects in antidepressant-exposed pregnancies found a small increase (3% to 24%) in the risk of major malformations and a risk of cardiovascular birth defects that did not differ from non-exposed pregnancies.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Einarson TR, Kennedy D, Einarson A<space/></arg><arg name="title"><space/>Do findings differ across research design? The case of antidepressant use in pregnancy and malformations<space/></arg><arg name="journal"><space/>J Popul Ther Clin Pharmacol<space/></arg><arg name="volume"><space/>19<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>e334–48<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22946124<space/></arg><arg name="doi"><space/></arg><arg name="url"><space/></arg></template></extension><space/>A study of fluoxetine-exposed pregnancies found a 12% increase in the risk of major malformations that just missed statistical significance.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Riggin L, Frankel Z, Moretti M, Pupco A, Koren G<space/></arg><arg name="title"><space/>The fetal safety of fluoxetine: a systematic review and meta-analysis<space/></arg><arg name="journal"><space/>J Obstet Gynaecol Can<space/></arg><arg name="volume"><space/>35<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>362–9<space/></arg><arg name="date">April 2013<space/></arg><arg name="pmid"><space/>23660045<space/></arg><arg name="doi"><space/></arg><arg name="url"><space/></arg></template></extension><space/>Other studies have found an increased risk of cardiovascular birth defects among depressed mothers not undergoing SSRI treatment, suggesting the possibility of ascertainment bias, e.g. that worried mothers may pursue more aggressive testing of their infants.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Koren G, Nordeng HM<space/></arg><arg name="title"><space/>Selective serotonin reuptake inhibitors and malformations: case closed?<space/></arg><arg name="journal"><space/>Semin Fetal Neonatal Med<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>19–22<space/></arg><arg name="date">February 2013<space/></arg><arg name="pmid"><space/>23228547<space/></arg><arg name="doi"><space/>10.1016/j.siny.2012.10.004<space/></arg><arg name="url"><space/></arg></template></extension><space/>Another study found no increase in cardiovascular birth defects and a 27% increased risk of major malformations in SSRI exposed pregnancies.<extension extension_name='ref' name="Nikfar S, Rahimi R, Hendoiee N, Abdollahi M 2012 75"></extension><space/>The FDA advises for the risk of birth defects with the use of paroxetine<extension extension_name='ref'><template><target>cite press release</target><arg name="publisher">U.S. Food and Drug Administration<space/></arg><arg name="title">FDA Advising of Risk of Birth Defects with Paxil<space/></arg><arg name="url">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108527.htm<space/></arg><arg name="accessdate">29 November 2012</arg><arg name="archiveurl">http://web.archive.org/web/20131203022919/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2005/ucm108527.htm<space/></arg><arg name="archivedate">3 December 2013<space/></arg></template></extension><space/>and the MAOI should be avoided.</paragraph><paragraph>A<space/><link><target>neonate</target></link><space/>(infant less than 28&amp;nbsp;days old) may experience a withdrawal syndrome from abrupt discontinuation of the antidepressant at birth. Antidepressants have been shown to be present in varying amounts in breast milk, but their effects on infants are currently unknown.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lanza di Scalea T, Wisner KL<space/></arg><arg name="title"><space/>Antidepressant Medication Use During Breastfeeding<space/></arg><arg name="journal"><space/>Clinical Obstetrics and Gynecology<space/></arg><arg name="volume"><space/>52<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>483–97<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19661763<space/></arg><arg name="pmc"><space/>2902256<space/></arg><arg name="doi"><space/>10.1097/GRF.0b013e3181b52bd6<space/></arg></template></extension></paragraph><paragraph>Moreover, SSRIs inhibit nitric oxide synthesis, which plays an important role in setting vascular tone. Several studies have pointed to an increased risk of prematurity associated with SSRI use, and this association may be due to an increase risk of<space/><link><target>pre-eclampsia</target></link><space/>of pregnancy.<extension extension_name='ref'><template><target>cite journal</target><arg name="last">Sivagnanam<space/></arg><arg name="first">G<space/></arg><arg name="title">Antidepressants<space/></arg><arg name="journal">Journal of Pharmacology and Pharmacotherapeutics<space/></arg><arg name="year">2012<space/></arg><arg name="volume">3<space/></arg><arg name="issue">3<space/></arg><arg name="pages">287–8<space/></arg><arg name="url">http://www.jpharmacol.com/text.asp?2012/3/3/287/99452</arg></template></extension></paragraph><heading level='3'>Antidepressant-induced mania</heading><paragraph>Another possible problem with antidepressants is the chance of antidepressant-induced mania in patients with<space/><link><target>bipolar disorder</target></link>. Many cases of bipolar depression are very similar to those of unipolar depression. Therefore, the patient can be misdiagnosed with unipolar depression and be given antidepressants. Studies have shown that antidepressant-induced mania can occur in 2040% of bipolar patients.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Goldberg JF, Truman CJ<space/></arg><arg name="title"><space/>Antidepressant-induced mania: An overview of current controversies<space/></arg><arg name="journal"><space/>Bipolar Disorders<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>407–20<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>14636364<space/></arg><arg name="doi"><space/>10.1046/j.1399-5618.2003.00067.x<space/></arg></template></extension><space/>For bipolar depression, antidepressants (most frequently SSRIs) can exacerbate or trigger symptoms of<space/><link><target>hypomania</target></link><space/>and<space/><link><target>mania</target></link>.<extension extension_name='ref' name="pmid9387089"><template><target>cite journal</target><arg name="author"><space/>Benazzi F<space/></arg><arg name="title"><space/>Antidepressant-associated hypomania in outpatient depression: a 203-case study in private practice<space/></arg><arg name="journal"><space/>J Affect Disord<space/></arg><arg name="volume"><space/>46<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>73–7<space/></arg><arg name="year"><space/>1997<space/></arg><arg name="pmid"><space/>9387089<space/></arg><arg name="doi"><space/>10.1016/S0165-0327(97)00082-7<space/></arg></template></extension></paragraph><heading level='3'>Suicide</heading><paragraph><template><target>Main</target><arg>Antidepressants and suicide risk</arg></template></paragraph><paragraph>Studies have shown that the use of antidepressants is correlated with an increased risk of suicidal behaviour and thinking (suicidality) in those aged under 25.<extension extension_name='ref' name="StoneETAL"></extension><space/>This problem has been serious enough to warrant government intervention by the US Food and Drug Administration (FDA) to warn of the increased risk of suicidality during antidepressant treatment.<extension extension_name='ref' name="pmid17485726"><template><target>cite journal</target><arg name="author"><space/>Friedman RA, Leon AC<space/></arg><arg name="title"><space/>Expanding the black box – depression, antidepressants, and the risk of suicide<space/></arg><arg name="journal"><space/>N. Engl. J. Med.<space/></arg><arg name="volume"><space/>356<space/></arg><arg name="issue"><space/>23<space/></arg><arg name="pages"><space/>2343–6<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17485726<space/></arg><arg name="doi"><space/>10.1056/NEJMp078015<space/></arg></template></extension><space/>According to the FDA, the heightened risk of suicidality is within the first one to two months of treatment.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm096273<space/></arg><arg name="title">Antidepressant Use in Children, Adolescents, and Adults<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088660.pdf%E2%80%8E<space/></arg><arg name="title">FDA Medication Guide for Antidepressants<space/></arg><arg name="accessdate">5 June 2014<space/></arg></template></extension><extension extension_name='ref' name="pmid23152255"><template><target>cite journal</target><arg name="author"><space/>Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, Hetrick SE<space/></arg><arg name="title"><space/>Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents<space/></arg><arg name="journal"><space/>Cochrane Database Syst Rev<space/></arg><arg name="volume"><space/>11<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>CD008324<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>23152255<space/></arg><arg name="doi"><space/>10.1002/14651858.CD008324.pub2<space/></arg></template></extension><template><target>Update inline</target><arg name="reason">Updated version https://www.ncbi.nlm.nih.gov/pubmed/25433518</arg><arg name="date">September 2015</arg></template><space/>The National Institute for Health and Care Excellence (NICE) places the excess risk in the &quot;early stages of treatment&quot;.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.nice.org.uk/nicemedia/pdf/CG90NICEguideline.pdf<space/></arg><arg name="title">www.nice.org.uk<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"></arg></template></extension><space/>A<space/><link><target>meta-analysis</target></link><space/>suggests that the relationship between antidepressant use and suicidal behavior or thoughts is age-dependent.<extension extension_name='ref' name="StoneETAL"></extension><space/>Compared to placebo the use of antidepressants is associated with an increase in suicidal behavior or thoughts among those aged under 25 (<link><target>odds ratio</target><part>OR</part></link>=1.62). This increase in suicidality approaches that observed in children and adolescents. There is no effect or possibly a mild protective effect among those aged 25 to 64 (OR=0.79). Antidepressant treatment has a protective effect against suicidality among those aged 65 and over (OR=0.37).<extension extension_name='ref' name="StoneETAL"><template><target>cite journal</target><arg name="author"><space/>Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, Hammad TA, Temple R, Rochester G<space/></arg><arg name="title"><space/>Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration<space/></arg><arg name="journal"><space/>BMJ<space/></arg><arg name="volume"><space/>339<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>b2880<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19671933<space/></arg><arg name="pmc"><space/>2725270<space/></arg><arg name="doi"><space/>10.1136/bmj.b2880</arg><arg name="url"><space/></arg></template></extension><extension extension_name='ref' name="dhintrev"><template><target>cite journal</target><arg name="author"><space/>Healy D, Aldred G<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="title"><space/>Antidepressant drug use and the risk of suicide<space/></arg><arg name="url"><space/>http://www.davidhealy.org.php53-23.dfw1-1.websitetestlink.com/wp-content/uploads/2012/05/2005-Healy-Aldred-Antidepressants-and-Suicide1.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="journal"><space/>International Review of Psychiatry<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>163–172<space/></arg><arg name="doi">10.1080/09540260500071624</arg></template></extension></paragraph><heading level='3'>Sexual</heading><paragraph>Sexual side-effects are also common with SSRIs, such as loss of<space/><link><target>sexual drive</target></link>,<space/><link><target>anorgasmia</target><part>failure to reach orgasm</part></link>, and<space/><link><target>erectile dysfunction</target></link>.<extension extension_name='ref'><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="editor-first">Jon E.<space/></arg><arg name="editor-last">Grant</arg><arg name="editor2-last">Potenza</arg><arg name="editor2-first">Marc N.<space/></arg><arg name="title">The Oxford handbook of impulse control disorders</arg><arg name="year">2012</arg><arg name="publisher">Oxford University Press</arg><arg name="location">Oxford</arg><arg name="isbn">978-0-19-538971-5</arg></template></extension><space/>Although usually reversible, these sexual side-effects can, in rare cases, last for months or years after the drug has been completely withdrawn.<extension extension_name='ref' name="pmid18173768"><template><target>cite journal</target><arg name="author"><space/>Csoka AB, Csoka A, Bahrick A, Mehtonen OP<space/></arg><arg name="title"><space/>Persistent sexual dysfunction after discontinuation of selective serotonin reuptake inhibitors<space/></arg><arg name="journal"><space/>J Sex Med<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>227–33<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18173768<space/></arg><arg name="doi"><space/>10.1111/j.1743-6109.2007.00630.x<space/></arg></template></extension></paragraph><paragraph>In a study of 1022 outpatients, overall sexual dysfunction with all antidepressants averaged 59.1%<extension extension_name='ref' name="pmid11229449"><template><target>cite journal</target><arg name="author"><space/>Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F<space/></arg><arg name="title"><space/>Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction<space/></arg><arg name="journal"><space/>J Clin Psychiatry<space/></arg><arg name="volume"><space/>62 Suppl 3<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>10–21<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="pmid"><space/>11229449<space/></arg><arg name="doi"><space/></arg></template></extension><space/>with SSRIs values between 57 and 73%, mirtazapine 24%, nefazodone 8%, amineptine 7% and moclobemide 4%.<space/><link><target>Moclobemide</target></link>, a selective reversible MAO-A inhibitor, does not cause sexual dysfunction,<extension extension_name='ref' name="pmid19440080"><template><target>cite journal</target><arg name="author"><space/>Serretti A, Chiesa A<space/></arg><arg name="title"><space/>Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis<space/></arg><arg name="journal"><space/>J Clin Psychopharmacol<space/></arg><arg name="volume"><space/>29<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>259–66<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19440080<space/></arg><arg name="doi"><space/>10.1097/JCP.0b013e3181a5233f<space/></arg></template></extension><space/>and can actually lead to an improvement in all aspects of sexual function.<extension extension_name='ref' name="pmid9696909"><template><target>cite journal</target><arg name="author"><space/>Chebili S, Abaoub A, Mezouane B, Le Goff JF<space/></arg><arg name="title"><space/>[Antidepressants and sexual stimulation: the correlation]<space/></arg><arg name="language"><space/>French<space/></arg><arg name="journal"><space/>Encephale<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>180–4<space/></arg><arg name="year"><space/>1998<space/></arg><arg name="pmid"><space/>9696909<space/></arg><arg name="doi"><space/></arg></template></extension></paragraph><paragraph>Biochemical mechanisms suggested as causative include increased serotonin, particularly affecting<space/><link><target>5-HT2 receptor</target><part>5-HT<xhtml:sub>2</xhtml:sub></part></link><space/>and<space/><link><target>5HT3 receptor</target><part>5-HT<xhtml:sub>3</xhtml:sub><space/>receptors</part></link>; decreased<space/><link><target>dopamine</target></link>; decreased<space/><link><target>norepinephrine</target></link>; blockade of<space/><link><target>cholinergic receptor</target><part>cholinergic</part></link><space/>and<space/><link><target>alpha-1 adrenergic receptor</target><part><xhtml:sub>1</xhtml:sub>adrenergic receptors</part></link>; inhibition of<space/><link><target>nitric oxide synthase</target><part>nitric oxide synthetase</part></link>; and elevation of<space/><link><target>prolactin</target></link><space/>levels.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Keltner NL, McAfee KM, Taylor CL<space/></arg><arg name="title"><space/>Biological Perspectives<space/></arg><arg name="journal"><space/>Perspectives in Psychiatric Care<space/></arg><arg name="volume"><space/>38<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>111–6<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>12385082<space/></arg><arg name="doi"><space/>10.1111/j.1744-6163.2002.tb00665.x<space/></arg></template></extension><space/><link><target>Mirtazapine</target></link><space/>is reported to have fewer sexual side-effects, most likely because it antagonizes 5-HT<xhtml:sub>2</xhtml:sub><space/>and 5-HT<xhtml:sub>3</xhtml:sub><space/>receptors and may, in some cases, reverse sexual dysfunction induced by SSRIs by the same mechanism.<extension extension_name='ref' name="pmid18278806"><template><target>cite journal</target><arg name="author"><space/>Ozmenler NK, Karlidere T, Bozkurt A, Yetkin S, Doruk A, Sutcigil L, Cansever A, Uzun O, Ozgen F, Ozsahin A<space/></arg><arg name="title"><space/>Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors<space/></arg><arg name="journal"><space/>Hum Psychopharmacol<space/></arg><arg name="volume"><space/>23<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>321–6<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18278806<space/></arg><arg name="doi"><space/>10.1002/hup.929<space/></arg></template></extension></paragraph><paragraph><link><target>Bupropion</target></link>, a weak NDRI and nicotinic antagonist, may be useful in treating reduced libido as a result of<space/><link><target>SSRI</target></link><space/>treatment.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Labbate LA, Grimes JB, Hines A, Pollack MH<space/></arg><arg name="title"><space/>Bupropion treatment of serotonin reuptake antidepressant-associated sexual dysfunction.<space/></arg><arg name="journal"><space/>Annals of Clinical Psychiatry<space/></arg><arg name="volume"><space/>9<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>241–5<space/></arg><arg name="date"><space/>December 1997<space/></arg><arg name="pmid"><space/>9511948<space/></arg><arg name="doi"><space/>10.3109/10401239709147804<space/></arg></template></extension></paragraph><heading level='3'>Changes in weight</heading><paragraph>Changes in appetite or weight are common among antidepressants, but largely drug-dependent and are related to which neurotransmitters they affect.<space/><link><target>Mirtazapine</target></link><space/>and<space/><link><target>paroxetine</target></link>, for example, have the effect of weight gain and/or increased appetite,<extension extension_name='ref' name="Stimmel"><template><target>cite journal</target><arg name="author"><space/>Stimmel GL, Dopheide JA, Stahl SM<space/></arg><arg name="title"><space/>Mirtazapine: An antidepressant with noradrenergic and specific serotonergic effects<space/></arg><arg name="journal"><space/>Pharmacotherapy<space/></arg><arg name="volume"><space/>17<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>10–21<space/></arg><arg name="year"><space/>1997<space/></arg><arg name="pmid"><space/>9017762<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="title">mirtazapine (Rx) – Remeron, Remeron SolTab<space/></arg><arg name="work">Medscape<space/></arg><arg name="publisher">WebMD<space/></arg><arg name="accessdate">19 November 2013<space/></arg><arg name="url">http://reference.medscape.com/drug/remeron-soltab-mirtazapine-342966</arg><arg name="archiveurl">http://web.archive.org/web/20131029200106/http://reference.medscape.com/drug/remeron-soltab-mirtazapine-342966<space/></arg><arg name="archivedate">29 October 2013<space/></arg></template></extension><extension extension_name='ref' name="autogenerated1032"><template><target>cite journal</target><arg name="author"><space/>Papakostas GI<space/></arg><arg name="title"><space/>Tolerability of modern antidepressants<space/></arg><arg name="journal"><space/>J Clin Psychiatry<space/></arg><arg name="volume"><space/>69<space/></arg><arg name="issue"><space/>Suppl E1<space/></arg><arg name="pages"><space/>8–13<space/></arg><arg name="year"><space/>2008<space/></arg><arg name="pmid"><space/>18494538<space/></arg></template></extension><space/>while others (such as<space/><link><target>bupropion</target></link><space/>and<space/><link><target>venlafaxine</target></link>) achieve the opposite effect.<extension extension_name='ref' name="Bupropion weight"><template><target>cite journal</target><arg name="author"><space/>Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR, Hilton L, Suttorp M, Solomon V, Shekelle PG, Morton SC<space/></arg><arg name="title"><space/>Meta-analysis: pharmacologic treatment of obesity<space/></arg><arg name="journal"><space/>Ann. Intern. Med.<space/></arg><arg name="volume"><space/>142<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>532–46<space/></arg><arg name="date"><space/>April 2005<space/></arg><arg name="pmid"><space/>15809465<space/></arg><arg name="doi"><space/>10.7326/0003-4819-142-7-200504050-00012<space/></arg></template></extension><extension extension_name='ref'><template><target>cite web</target><arg name="year">2006<space/></arg><arg name="title">Effexor Medicines Data Sheet<space/></arg><arg name="publisher">Wyeth Pharmaceuticals Inc<space/></arg><arg name="url">http://www.wyeth.com/content/showlabeling.asp?id</arg><arg name="accessdate">17 September 2006<space/></arg><arg name="archiveurl">https://web.archive.org/web/20060917025654/http://www.wyeth.com/content/ShowLabeling.asp?id</arg><arg name="archivedate">17 September 2006</arg></template></extension></paragraph><paragraph>The<space/><link><target>antihistamine</target><part>antihistaminic</part></link><space/>properties of certain TCA- and TeCA-class antidepressants have been shown to contribute to the common side-effects of increased appetite and weight gain associated with these classes of medication.</paragraph><heading level='3'>Discontinuation syndrome</heading><paragraph><template><target>Main</target><arg>Antidepressant discontinuation syndrome</arg></template></paragraph><paragraph>Antidepressant discontinuation symptoms were first reported with<space/><link><target>imipramine</target></link>, the first tricyclic antidepressant (TCA), in the late 1950s, and each new class of antidepressants has brought reports of similar conditions, including<space/><link><target>monoamine oxidase inhibitors</target></link><space/>(MAOIs), SSRIs, and SNRIs. As of 2001, at least 21 different antidepressants, covering all the major classes, were known to cause discontinuation syndromes.<extension extension_name='ref' name="DrugSaf2001-Haddad"><template><target>cite journal</target><arg name="author">Haddad, P.<space/></arg><arg name="title">Antidepressant discontinuation syndromes<space/></arg><arg name="journal">Drug Saf<space/></arg><arg name="volume">24<space/></arg><arg name="issue">3<space/></arg><arg name="pages">183–97<space/></arg><arg name="year">2001<space/></arg><arg name="pmid">11347722<space/></arg><arg name="doi">10.2165/00002018-200124030-00003</arg></template></extension><space/>The problem has been poorly studied, and most of the literature has been case reports or small clinical studies; incidence is hard to determine and controversial.<extension extension_name='ref' name="DrugSaf2001-Haddad"></extension></paragraph><paragraph>People with discontinuation syndrome have been on an antidepressant for at least four weeks and have recently stopped taking the medication, either abruptly or after a fast taper.<extension extension_name='ref' name="WarnerAFP"><template><target>cite journal</target><arg name="author">Warner CH, Bobo W, Warner C, Reid S, Rachal J<space/></arg><arg name="title">Antidepressant discontinuation syndrome<space/></arg><arg name="journal">Am Fam Physician<space/></arg><arg name="volume">74<space/></arg><arg name="issue">3<space/></arg><arg name="pages">449–56<space/></arg><arg name="date">August 2006<space/></arg><arg name="pmid">16913164<space/></arg><arg name="doi"><space/></arg><arg name="url"></arg></template></extension><space/>Common symptoms include flu-like symptoms (nausea, vomiting, diarrhea, headaches, sweating), sleep disturbances (insomnia, nightmares, constant sleepiness), sensory/movement disturbances (imbalance, tremors,<space/><link><target>Vertigo (medical)</target><part>vertigo</part></link>, dizziness, electric-shock-like experiences), mood disturbances (<link><target>dysphoria</target></link>, anxiety, agitation) and cognitive disturbances (confusion and hyperarousal).<extension extension_name='ref' name="WarnerAFP"></extension><extension extension_name='ref' name="Haddad2007"><template><target>cite journal</target><arg name="last">Haddad<space/></arg><arg name="first">P.M.<space/></arg><arg name="last2">Anderson<space/></arg><arg name="first2">I.M.<space/></arg><arg name="year">2007<space/></arg><arg name="title">Recognising and managing antidepressant discontinuation symptoms<space/></arg><arg name="journal">Advances in Psychiatric Treatment<space/></arg><arg name="volume">13<space/></arg><arg name="issue">6<space/></arg><arg name="pages">447–457<space/></arg><arg name="doi">10.1192/apt.bp.105.001966</arg></template></extension><extension extension_name='ref' name="Renoir2013"><template><target>cite journal</target><arg name="author"><space/>Renoir T<space/></arg><arg name="date">April 2013<space/></arg><arg name="title"><space/>Selective serotonin reuptake inhibitor antidepressant treatment discontinuation syndrome: a review of the clinical evidence and the possible mechanisms involved<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Front Pharmacol<space/></arg><arg name="volume"><space/>4<space/></arg><arg name="issue"><space/></arg><arg name="page"><space/>45<space/></arg><arg name="doi"><space/>10.3389/fphar.2013.00045<space/></arg><arg name="pmid"><space/>23596418<space/></arg><arg name="pmc">3627130</arg></template></extension><space/>Over fifty symptoms have been reported.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Haddad PM, Dursun SM<space/></arg><arg name="date">January 2008<space/></arg><arg name="title"><space/>Neurological complications of psychiatric drugs: clinical features and management<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Hum Psychopharmacol<space/></arg><arg name="volume"><space/>23<space/></arg><arg name="issue"><space/>Suppl 1</arg><arg name="pages"><space/>15–26<space/></arg><arg name="pmid"><space/>18098217<space/></arg><arg name="doi">10.1002/hup.918</arg></template></extension></paragraph><paragraph>Most cases of discontinuation syndrome last between one and four weeks, are relatively mild, and resolve on their own; in rare cases symptoms can be severe or extended.<extension extension_name='ref' name="WarnerAFP"></extension><space/>Paroxetine and venlafaxine seem to be particularly difficult to discontinue and prolonged withdrawal syndrome lasting over 18 months have been reported with paroxetine.<extension extension_name='ref' name="DrugSaf2001-Haddad"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last">Tamam<space/></arg><arg name="first">L.<space/></arg><arg name="last2">Ozpoyraz<space/></arg><arg name="first2">N.<space/></arg><arg name="title">Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome: A Review<space/></arg><arg name="journal">Advances in Therapy<space/></arg><arg name="date">January–February 2002<space/></arg><arg name="volume">19<space/></arg><arg name="issue">1<space/></arg><arg name="pages">17–26<space/></arg><arg name="url">http://link.springer.com/article/10.1007%2FBF02850015?LI</arg><arg name="accessdate">28 November 2012<space/></arg><arg name="doi">10.1007/BF02850015<space/></arg><arg name="pmid">12008858</arg></template></extension><extension extension_name='ref' name="2ndGenReview">Gartlehner G, Hansen RA, Morgan LC, et al.<space/><link type='external' href='http://www.ncbi.nlm.nih.gov/books/NBK83447/'>Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review &amp;#91;Internet&amp;#93;.</link><space/>Comparative Effectiveness Reviews, No. 46. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Dec.</extension></paragraph><paragraph>With the explosion of use and interest in SSRIs in the late 1980s and early 1990s, focused especially on<space/><link><target>Prozac#Popular culture</target><part>Prozac</part></link>, interest grew as well in discontinuation syndromes.<extension extension_name='ref'><template><target>cite news</target><arg name="url">http://www.nytimes.com/2007/05/06/magazine/06antidepressant-t.html</arg><arg name="work">New York Times<space/></arg><arg name="title">Self-Nonmedication<space/></arg><arg name="first">Bruce<space/></arg><arg name="last">Stutz<space/></arg><arg name="date">6 May 2007<space/></arg><arg name="accessdate">24 May 2010</arg></template></extension><space/>In the late 1990s, some investigators thought that symptoms that emerged when antidepressants were discontinued, might mean that antidepressants were causing<space/><link><target>addiction</target></link>, and some used the term &quot;withdrawal syndrome&quot; to describe the symptoms. Addictive substances cause<space/><link><target>physiological dependence</target></link>, so that<space/><link><target>drug withdrawal</target></link><space/>causes suffering. These theories were abandoned, since addiction leads to<space/><link><target>drug-seeking behavior</target></link>, and people taking antidepressants do not exhibit drug-seeking behavior. The term &quot;withdrawal syndrome&quot; is no longer used with respect to antidepressants, to avoid confusion with problems that arise from addiction.<extension extension_name='ref' name="WarnerAFP"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Shelton RC<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="title"><space/>The nature of the discontinuation syndrome associated with antidepressant drugs<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>J Clin Psychiatry<space/></arg><arg name="volume"><space/>67<space/></arg><arg name="issue"><space/>Suppl 4</arg><arg name="pages"><space/>3–7<space/></arg><arg name="pmid"><space/>16683856<space/></arg></template></extension><extension extension_name='ref'>WHO (2003)<space/><link type='external' href='http://apps.who.int/medicinedocs/fr/d/Js4896e/9.html'>WHO Expert Committee on Drug Dependence WHO Technical Report Series, No. 915 Thirty-third Report</link></extension><space/>There are case reports of antidepressants being abused, but these are rare and are mostly limited to antidepressants with stimulant effects and to people who already had a substance use disorder.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Evans EA, Sullivan MA<space/></arg><arg name="date"><space/>Aug 2014<space/></arg><arg name="title"><space/>Abuse and misuse of antidepressants<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Subst Abuse Rehabil<space/></arg><arg name="volume"><space/>5<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>107–20<space/></arg><arg name="doi"><space/>10.2147/SAR.S37917<space/></arg><arg name="pmid"><space/>25187753<space/></arg></template></extension><space/>A 2012 comparison of the effects of stopping therapy with<space/><link><target>benzodiazepines</target></link><space/>and<space/><link><target>SSRI</target><trail>s</trail></link><space/>argued that because the symptoms are similar, it makes no sense to say that benzodiazepines are addictive while SSRIs are not.<extension extension_name='ref'><template><target>cite journal</target><arg name="vauthors">Nielsen M, et al.<space/></arg><arg name="date"><space/>May 2012<space/></arg><arg name="title"><space/>What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Addiction<space/></arg><arg name="volume"><space/>107<space/></arg><arg name="issue"><space/>5</arg><arg name="pages"><space/>900–8<space/></arg><arg name="doi"><space/>10.1111/j.1360-0443.2011.03686.x<space/></arg><arg name="pmid"><space/>21992148<space/></arg></template></extension><space/>Responses to that review noted that there is no evidence that people who stop taking SSRIs exhibit drug-seeking behavior while people who stop taking benzodiazepines do, and that the drug classes should be considered differently.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Brady K<space/></arg><arg name="date"><space/>May 2012<space/></arg><arg name="title"><space/>Withdrawal or dependence: a matter of context. Comment on: What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Addiction<space/></arg><arg name="volume"><space/>107<space/></arg><arg name="issue"><space/>5</arg><arg name="pages"><space/>910–1<space/></arg><arg name="doi"><space/>10.1111/j.1360-0443.2012.03862.x<space/></arg><arg name="pmid"><space/>22471576<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Lader M<space/></arg><arg name="date"><space/>May 2012<space/></arg><arg name="title"><space/>Dependence and withdrawal: comparison of the benzodiazepines and selective serotonin re-uptake inhibitors. Comment on: What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors<space/></arg><arg name="url"><space/></arg><arg name="journal"><space/>Addiction<space/></arg><arg name="volume"><space/>107<space/></arg><arg name="issue"><space/>5</arg><arg name="pages"><space/>909–10<space/></arg><arg name="doi"><space/>10.1111/j.1360-0443.2011.03736.x<space/></arg><arg name="pmid"><space/>22471575<space/></arg></template></extension></paragraph><heading level='2'>Pharmacology</heading><paragraph><template><target>Main</target><arg>Pharmacology of antidepressants</arg></template>The earliest and probably most widely accepted scientific theory of antidepressant action is the<space/><link><target>monoamine hypothesis</target></link><space/>(which can be traced back to the 1950s), which states that depression is due to an imbalance (most often a deficiency) of the<space/><link><target>monoamine neurotransmitter</target><trail>s</trail></link><space/>(namely<space/><link><target>serotonin</target></link>,<space/><link><target>norepinephrine</target></link><space/>and<space/><link><target>dopamine</target></link>).<extension extension_name='ref' name="GG"></extension><space/>It was originally proposed based on the observation that certain hydrazine anti-tuberculosis agents produce antidepressant effects, which was later linked to their inhibitory effects on<space/><link><target>monoamine oxidase</target></link>, the enzyme that catalyses the breakdown of the monoamine neurotransmitters.<extension extension_name='ref' name="GG"></extension><space/>All currently marketed antidepressants have the monoamine hypothesis as their theoretical basis, with the possible exception of<space/><link><target>agomelatine</target></link><space/>which acts on a dual<space/><link><target>Melatonin</target><part>melatonergic</part></link>-<link><target>Serotonin</target><part>serotonergic</part></link><space/>pathway.<extension extension_name='ref' name="GG"></extension><space/>Despite the success of the monoamine hypothesis it has a number of limitations: for one, all monoaminergic antidepressants have a delayed onset of action of at least a week; and secondly, there are a sizeable portion (&gt;40%) of depressed patients that do not adequately respond to monoaminergic antidepressants.<extension extension_name='ref' name="Infl"><template><target>cite journal</target><arg name="author"><space/>Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M<space/></arg><arg name="title"><space/>The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression<space/></arg><arg name="journal"><space/>Metabolic Brain Disease<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>27–53<space/></arg><arg name="date"><space/>March 2009<space/></arg><arg name="pmid"><space/>19085093<space/></arg><arg name="doi"><space/>10.1007/s11011-008-9118-1<space/></arg></template></extension><extension extension_name='ref' name="glut"><template><target>cite journal</target><arg name="author"><space/>Sanacora G, Treccani G, Popoli M<space/></arg><arg name="title"><space/>Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders<space/></arg><arg name="journal"><space/>Neuropharmacology<space/></arg><arg name="volume"><space/>62<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>63–77<space/></arg><arg name="date"><space/>January 2012<space/></arg><arg name="pmid"><space/>21827775<space/></arg><arg name="doi"><space/>10.1016/j.neuropharm.2011.07.036<space/></arg><arg name="url"><space/>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205453/pdf/nihms318867.pdf<space/></arg><arg name="format"><space/>PDF<space/></arg><arg name="accessdate"><space/></arg><arg name="pmc">3205453</arg></template></extension><space/>A number of alternative hypotheses have been proposed, including the glutamate, neurogenic,<space/><link><target>Epigenetics</target><part>epigenetic</part></link>, cortisol hypersecretion and inflammatory hypotheses.<extension extension_name='ref' name="Infl"></extension><extension extension_name='ref' name="glut"></extension><extension extension_name='ref' name="Epig"><template><target>cite journal</target><arg name="author"><space/>Menke A, Klengel T, Binder EB<space/></arg><arg name="title"><space/>Epigenetics, depression and antidepressant treatment<space/></arg><arg name="journal"><space/>Current Pharmaceutical Design<space/></arg><arg name="volume"><space/>18<space/></arg><arg name="issue"><space/>36<space/></arg><arg name="pages"><space/>5879–5889<space/></arg><arg name="year"><space/>2012<space/></arg><arg name="pmid"><space/>22681167<space/></arg><arg name="doi"><space/>10.2174/138161212803523590<space/></arg></template></extension><extension extension_name='ref' name="Epig2"><template><target>cite journal</target><arg name="author"><space/>Vialou V, Feng J, Robison AJ, Nestler EJ<space/></arg><arg name="title"><space/>Epigenetic mechanisms of depression and antidepressant action<space/></arg><arg name="journal"><space/>Annual Review of Pharmacology and Toxicology<space/></arg><arg name="volume"><space/>53<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>59–87<space/></arg><arg name="date"><space/>January 2013<space/></arg><arg name="pmid"><space/>23020296<space/></arg><arg name="doi"><space/>10.1146/annurev-pharmtox-010611-134540<space/></arg></template></extension></paragraph><heading level='2'>Types</heading><paragraph><template><target>See also</target><arg>List of antidepressants</arg></template></paragraph><heading level='2'>Adjuncts</heading><paragraph>Adjunct medications are an umbrella term used to describe substances that increase the potency or &quot;enhance&quot; antidepressants.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.merckmanuals.com/professional/psychiatric_disorders/mood_disorders/depressive_disorders.html?qt</arg><arg name="work">Merck Manual<space/></arg><arg name="title">Depressive Disorders<space/></arg><arg name="accessdate">30 November 2012</arg><arg name="archiveurl">http://web.archive.org/web/20131205163219/http://www.merckmanuals.com/professional/psychiatric_disorders/mood_disorders/depressive_disorders.html?qt</arg><arg name="archivedate">5 December 2013<space/></arg></template></extension><space/>They work by affecting variables very close to the antidepressant, sometimes affecting a completely different<space/><link><target>mechanism of action</target></link>. This may be attempted when depression treatments have not been successful in the past.</paragraph><paragraph>Common types of adjunct medication techniques generally fall into the following categories:</paragraph><list type='bullet'><listitem>Two or more antidepressants taken together<list type='bullet'><listitem>From the same class (affecting the same area of the brain, often at a much higher level)</listitem><listitem>From different classes (affecting multiple parts of the brain not covered simultaneously by either drug alone)</listitem></list></listitem><listitem>An<space/><link><target>antipsychotic</target></link><space/>combined with an antidepressant, particularly<space/><link><target>atypical antipsychotic</target><trail>s</trail></link><space/>such as<space/><link><target>aripiprazole</target></link><space/>(Abilify),<space/><link><target>quetiapine</target></link><space/>(Seroquel),<space/><link><target>olanzapine</target></link><space/>(Zyprexa), and<space/><link><target>risperidone</target></link><space/>(Risperdal).<extension extension_name='ref' name="Maudsley"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1">Taylor<space/></arg><arg name="first1">D<space/></arg><arg name="last2">Carol<space/></arg><arg name="first2">P<space/></arg><arg name="last3">Shitij<space/></arg><arg name="first3">K<space/></arg><arg name="title">The Maudsley prescribing guidelines in psychiatry<space/></arg><arg name="year">2012<space/></arg><arg name="publisher">Wiley-Blackwell<space/></arg><arg name="location">West Sussex<space/></arg><arg name="isbn">978-0-470-97969-3</arg></template></extension></listitem></list><heading level='3'>Less common adjunct medication</heading><paragraph>Lithium has been used to augment antidepressant therapy in those who have failed to respond to antidepressants alone.<extension extension_name='ref' name="pmid10505584"><template><target>cite journal</target><arg name="author">Bauer M, Dopfmer S<space/></arg><arg name="year">1999<space/></arg><arg name="title">Lithium augmentation in treatment-resistant depression: Meta-analysis of placebo-controlled studies<space/></arg><arg name="journal">Journal of Clinical Psychopharmacology<space/></arg><arg name="volume">19<space/></arg><arg name="issue">5<space/></arg><arg name="pages">427–34<space/></arg><arg name="pmid">10505584<space/></arg><arg name="doi">10.1097/00004714-199910000-00006<space/></arg><arg name="ref">harv</arg></template></extension><space/>Furthermore, lithium dramatically decreases the suicide risk in recurrent depression.<extension extension_name='ref' name="pmid17388706"><template><target>cite journal</target><arg name="author">Guzzetta F, Tondo L, Centorrino F, Baldessarini RJ<space/></arg><arg name="title">Lithium treatment reduces suicide risk in recurrent major depressive disorder<space/></arg><arg name="journal">J Clin Psychiatry<space/></arg><arg name="volume">68<space/></arg><arg name="issue">3<space/></arg><arg name="pages">380–83<space/></arg><arg name="date">March 2007<space/></arg><arg name="pmid">17388706<space/></arg><arg name="doi">10.4088/JCP.v68n0304<space/></arg><arg name="url">http://article.psychiatrist.com/?ContentType</arg><arg name="ref">harv</arg></template></extension><space/>There is some evidence for the addition of a thyroid hormone,<space/><link><target>triiodothyronine</target></link>, in patients with normal thyroid function.<extension extension_name='ref' name="pmid16946176"><template><target>cite journal</target><arg name="author">Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K, Rush AJ<space/></arg><arg name="year">2006<space/></arg><arg name="title">A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report<space/></arg><arg name="journal">American Journal of Psychiatry<space/></arg><arg name="volume">163<space/></arg><arg name="issue">9<space/></arg><arg name="pages">1519–30<space/></arg><arg name="pmid">16946176<space/></arg><arg name="doi">10.1176/appi.ajp.163.9.1519<space/></arg><arg name="ref">harv</arg></template></extension><space/>Stephen M. Stahl, renowned academician in psychopharmacology, has stated resorting to a dynamic<space/><link><target>psychostimulant</target></link>, in particular,<space/><link><target>d-amphetamine</target></link><space/>is the &quot;<italics>classical augmentation strategy</italics><space/>for treatment-refractory depression&quot;.<extension extension_name='ref'><template><target>cite book</target><arg name="last">Stahl</arg><arg name="first">Stephen M.</arg><arg name="title">The Prescriber's Guide (Stahl's Essential Psychopharmacology)</arg><arg name="year">2011</arg><arg name="publisher">Cambridge University Press</arg><arg name="page">39</arg></template></extension><space/>However, the use of stimulants in cases of treatment-resistant depression is relatively controversial.<extension extension_name='ref' name="pmid1411740"><template><target>cite journal</target><arg name="author"><space/>Kraus MF, Burch EA<space/></arg><arg name="title"><space/>Methylphenidate hydrochloride as an antidepressant: controversy, case studies, and review<space/></arg><arg name="journal"><space/>South. Med. J.<space/></arg><arg name="volume"><space/>85<space/></arg><arg name="issue"><space/>10<space/></arg><arg name="pages"><space/>985–91<space/></arg><arg name="year"><space/>1992<space/></arg><arg name="pmid"><space/>1411740<space/></arg><arg name="doi"><space/>10.1097/00007611-199210000-00012<space/></arg></template></extension><extension extension_name='ref' name="pmid17338594"><template><target>cite journal</target><arg name="last1">Orr</arg><arg name="first1">K</arg><arg name="last2">Taylor</arg><arg name="first2">D</arg><arg name="title">Psychostimulants in the treatment of depression : a review of the evidence.</arg><arg name="journal">CNS drugs</arg><arg name="date">2007</arg><arg name="volume">21</arg><arg name="issue">3</arg><arg name="pages">239–57</arg><arg name="pmid">17338594</arg><arg name="doi">10.2165/00023210-200721030-00004</arg></template></extension><space/>A review article published in 2007 found psychostimulants may be effective in treatment-resistant depression with concomitant antidepressant therapy, but a more certain conclusion could not be drawn due to substantial deficiencies in the studies available for consideration, and the somewhat contradictory nature of their results.<extension extension_name='ref' name="pmid17338594"></extension></paragraph><heading level='2'>History</heading><paragraph><link><target>File:Saint johns wart flowers.jpg</target><part>thumb</part><part>alt=refer to caption</part><part><link><target>Hypericum perforatum</target><part>St John's wort</part></link></part></link>Before the 1950s,<space/><link><target>opioid</target><trail>s</trail></link><space/>and<space/><link><target>amphetamine</target><trail>s</trail></link><space/>were commonly used as antidepressants.<extension extension_name='ref' name="Weber 1988 25566"><template><target>cite journal</target><arg name="author"><space/>Weber MM, Emrich HM<space/></arg><arg name="title"><space/>Current and Historical Concepts of Opiate Treatment in Psychiatric Disorders<space/></arg><arg name="journal"><space/>International Clinical Psychopharmacology<space/></arg><arg name="volume"><space/>3<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>255–66<space/></arg><arg name="year"><space/>1988<space/></arg><arg name="pmid"><space/>3153713<space/></arg><arg name="doi"><space/>10.1097/00004850-198807000-00007<space/></arg></template></extension><extension extension_name='ref' name="Amph Uses Dex"><template><target>cite journal</target><arg name="author"><space/>Heal DJ, Smith SL, Gosden J, Nutt DJ<space/></arg><arg name="title"><space/>Amphetamine, past and present – a pharmacological and clinical perspective<space/></arg><arg name="journal"><space/>J. Psychopharmacol.<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>479–96<space/></arg><arg name="date">June 2013<space/></arg><arg name="pmid"><space/>23539642<space/></arg><arg name="pmc"><space/>3666194<space/></arg><arg name="doi"><space/>10.1177/0269881113482532</arg></template></extension><space/>Their use was later restricted due to their addictive nature and side effects.<extension extension_name='ref' name="Weber 1988 25566"></extension><space/>Extracts from the herb<space/><link><target>Hypericum perforatum</target><part>St John's wort</part></link><space/>had been used as a &quot;nerve tonic&quot; to alleviate depression.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Czygan FC<space/></arg><arg name="title"><space/>Kulturgeschichte und Mystik des Johanniskrauts: Vom 2500 Jahre alten Apotropaikum zum aktuellen Antidepressivum<space/></arg><arg name="language"><space/>German<space/></arg><arg name="journal"><space/>Pharmazie in unserer Zeit<space/></arg><arg name="volume"><space/>32<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>184–90<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12784538<space/></arg><arg name="doi"><space/>10.1002/pauz.200390062<space/></arg><arg name="trans_title"><space/>From a 2500-year-old apotropic comes a current antidepressive. The cultural history and mistique of St. John's wort<space/></arg></template></extension></paragraph><heading level='3'>Isoniazid, iproniazid, and imipramine</heading><paragraph>In 1951,<space/><link><target>Irving Selikoff</target></link><space/>and Edward Robitzek, working out of Sea View Hospital on<space/><link><target>Staten Island</target></link>, began clinical trials on two new<space/><link><target>tuberculosis</target><part>anti-tuberculosis</part></link><space/>agents developed by Hoffman-LaRoche,<space/><link><target>isoniazid</target></link><space/>and<space/><link><target>iproniazid</target></link>. Only patients with a poor<space/><link><target>prognosis</target></link><space/>were initially treated; nevertheless, their condition improved dramatically. Selikoff and Robitzek noted &quot;a subtle general stimulation the patients exhibited renewed vigor and indeed this occasionally served to introduce disciplinary problems.&quot;<extension extension_name='ref' name="pmid14906149"><template><target>cite journal</target><arg name="author"><space/>Selikoff IJ, Robitzek EH<space/></arg><arg name="title"><space/>Tuberculosis Chemotherapy with Hydrazine Derivatives of Isonicotinic Acid<space/></arg><arg name="journal"><space/>CHEST Journal<space/></arg><arg name="volume"><space/>21<space/></arg><arg name="issue"><space/>4<space/></arg><arg name="pages"><space/>385–438<space/></arg><arg name="year"><space/>1952<space/></arg><arg name="pmid"><space/>14906149<space/></arg><arg name="doi"><space/>10.1378/chest.21.4.385<space/></arg></template></extension><space/>The promise of a cure for tuberculosis in the Sea View Hospital trials was excitedly discussed in the mainstream press.</paragraph><paragraph>In 1952, learning of the stimulating side effects of isoniazid, the Cincinnati psychiatrist Max Lurie tried it on his patients. In the following year, he and Harry Salzer reported that isoniazid improved depression in two thirds of their patients and coined the term<space/><italics>antidepressant</italics><space/>to describe its action.<extension extension_name='ref' name="isbn0-88048-397-0"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last">Healy<space/></arg><arg name="first">D<space/></arg><arg name="editor1-last">Weissman<space/></arg><arg name="editor1-first">M.M.<space/></arg><arg name="title">The treatment of depression: bridging the 21st century<space/></arg><arg name="url">http://books.google.com/?id</arg><arg name="accessdate">28 May 2009<space/></arg><arg name="year">2001<space/></arg><arg name="publisher">American Psychiatric Pub<space/></arg><arg name="isbn">978-0-88048-397-1<space/></arg><arg name="pages">10–11<space/></arg><arg name="chapter">The Antidepressant Drama<space/></arg><arg name="chapterurl">http://books.google.co.uk/books?id</arg></template></extension><space/>A similar incident took place in Paris, where Jean Delay, head of psychiatry at Sainte-Anne Hospital, heard of this effect from his<space/><link><target>pulmonology</target></link><space/>colleagues at Cochin Hospital. In 1952 (before Lurie and Salzer), Delay, with the resident Jean-Francois Buisson, reported the positive effect of isoniazid on depressed patients.<extension extension_name='ref' name="Healy96"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last">Healy<space/></arg><arg name="first">David<space/></arg><arg name="title">The psychopharmacologists: interviews<space/></arg><arg name="year">1996<space/></arg><arg name="publisher">Chapman and Hall<space/></arg><arg name="location">London<space/></arg><arg name="isbn">978-1-86036-008-4<space/></arg><arg name="page">8</arg></template></extension><space/>The mode of antidepressant action of isoniazid is still unclear. It is speculated that its effect is due to the inhibition of<space/><link><target>diamine oxidase</target></link>, coupled with a weak inhibition of<space/><link><target>monoamine oxidase A</target></link>.<extension extension_name='ref' name="isbn1-86036-010-6"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last">Healy<space/></arg><arg name="first">David<space/></arg><arg name="title">The Psychopharmacologists: Volume 2<space/></arg><arg name="publisher">A Hodder Arnold Publication<space/></arg><arg name="year">1998<space/></arg><arg name="pages">132–4<space/></arg><arg name="isbn">978-1-86036-010-7</arg></template></extension></paragraph><paragraph>Selikoff and Robitzek also experimented with another anti-tuberculosis drug,<space/><link><target>iproniazid</target></link>; it showed a greater psychostimulant effect, but more pronounced toxicity.<extension extension_name='ref' name="pmid12998444"><template><target>cite journal</target><arg name="author"><space/>Robitzek EH, Selikoff IJ, Mamlok E, Tendlau A<space/></arg><arg name="title"><space/>Isoniazid and Its Isopropyl Derivative in the Therapy of Tuberculosis in Humans: Comparative Therapeutic and Toxicologic Properties<space/></arg><arg name="journal"><space/>CHEST Journal<space/></arg><arg name="volume"><space/>23<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>1–15<space/></arg><arg name="year"><space/>1953<space/></arg><arg name="pmid"><space/>12998444<space/></arg><arg name="doi"><space/>10.1378/chest.23.1.1<space/></arg></template></extension><space/>Later, Jackson Smith, Gordon Kamman, George Crane, and<space/><link><target>Frank Ayd</target></link>, described the psychiatric applications of iproniazid. Ernst Zeller found iproniazid to be a potent<space/><link><target>monoamine oxidase inhibitor</target></link>.<extension extension_name='ref' name="pmid18004120"><template><target>cite journal</target><arg name="author"><space/>López-Muñoz F, Alamo C, Juckel G, Assion HJ<space/></arg><arg name="title"><space/>Half a Century of Antidepressant Drugs<space/></arg><arg name="journal"><space/>Journal of Clinical Psychopharmacology<space/></arg><arg name="volume"><space/>27<space/></arg><arg name="issue"><space/>6<space/></arg><arg name="pages"><space/>555–9<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>18004120<space/></arg><arg name="doi"><space/>10.1097/jcp.0b013e3181bb617<space/></arg></template></extension><space/>Nevertheless, iproniazid remained relatively obscure until Nathan Kline, the influential and flamboyant head of research at Rockland State Hospital, began to popularize it in the medical and popular press as a &quot;psychic energizer&quot;.<extension extension_name='ref' name="pmid18004120"></extension><extension extension_name='ref'><template><target>cite news</target><arg name="title">Psychic Energizer<space/></arg><arg name="url">http://www.time.com/time/magazine/article/0,9171,862555,00.html<space/></arg><arg name="date">15 April 1957<space/></arg><arg name="work">Time<space/></arg><arg name="accessdate">28 May 2009</arg><arg name="archiveurl">http://web.archive.org/web/20130811223331/http://www.time.com/time/magazine/article/0,9171,862555,00.html<space/></arg><arg name="archivedate">11 August 2013<space/></arg></template></extension><space/>Roche put a significant marketing effort behind iproniazid.<extension extension_name='ref' name="pmid18004120"></extension><space/>Its sales grew until it was recalled in 1961, due to reports of lethal<space/><link><target>hepatotoxicity</target></link>.<extension extension_name='ref' name="pmid18004120"></extension></paragraph><paragraph>The antidepressant effect of a<space/><link><target>tricyclic</target></link>, a three ringed compound, was first discovered in 1957 by<space/><link><target>Roland Kuhn</target></link><space/>in a Swiss<space/><link><target>psychiatric hospital</target></link>.<space/><link><target>Antihistamine</target></link><space/>derivatives were used to treat surgical shock and later as<space/><link><target>neuroleptics</target></link>. Although in 1955<space/><link><target>reserpine</target></link><space/>was shown to be more effective than placebo in alleviating anxious depression, neuroleptics were being developed as<space/><link><target>sedatives</target></link><space/>and<space/><link><target>antipsychotics</target></link>.<template><target>medical citation needed</target><arg name="date">March 2013</arg></template></paragraph><paragraph>Attempting to improve the effectiveness of<space/><link><target>chlorpromazine</target></link>, Kuhn<template><target>spaced ndash</target></template><space/>in conjunction with the<space/><link><target>Geigy</target></link><space/><link><target>Pharmaceutical Company</target></link><template><target>spaced ndash</target></template><space/>discovered the compound &quot;G 22355&quot;, later renamed<space/><link><target>imipramine</target></link>. Imipramine had a beneficial effect in patients with depression who showed mental and<space/><link><target>motor retardation</target></link>. Kuhn described his new compound as a &quot;thymoleptic&quot; &quot;taking hold of the emotions,&quot; in contrast with neuroleptics, &quot;taking hold of the nerves&quot; in 195556. These gradually became established, resulting in the patent and manufacture in the US in 1951 by Hfliger and SchinderA.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Kuhn R<space/></arg><arg name="title"><space/>The treatment of depressive states with G 22355 (imipramine hydrochloride)<space/></arg><arg name="journal"><space/>The American Journal of Psychiatry<space/></arg><arg name="volume"><space/>115<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>459–64<space/></arg><arg name="year"><space/>1958<space/></arg><arg name="pmid"><space/>13583250<space/></arg></template></extension></paragraph><heading level='3'>Second generation antidepressants</heading><paragraph><template><target>Main</target><arg>Second-generation antidepressants</arg></template></paragraph><paragraph>Antidepressants became<space/><link><target>prescription drug</target><trail>s</trail></link><space/>in the 1950s. It was estimated that no more than 50 to 100 individuals per million suffered from the kind of depression that these new drugs would treat, and pharmaceutical companies were not enthusiastic in marketing for this small market. Sales through the 1960s remained poor compared to the sales of tranquilizers,<extension extension_name='ref'><template><target>cite web</target><arg name="title">Tranquilizers<space/></arg><arg name="url">http://www.cmcsb.com/tranquil.htm<space/></arg><arg name="work">Cumberland Moutain Community Services<space/></arg><arg name="publisher">www.cmcsb.com<space/></arg><arg name="accessdate">20 November 2013<space/></arg><arg name="archiveurl">https://web.archive.org/web/20120916074410/http://www.cmcsb.com/tranquil.htm<space/></arg><arg name="archivedate">16 September 2012</arg></template><template><target>Unreliable medical source</target><arg name="date">March 2013</arg></template></extension><space/>which were being marketed for different uses.<extension extension_name='ref' name="3faces"><template><target>cite journal</target><arg name="author"><space/>Healy D<space/></arg><arg name="title"><space/>The Three Faces of the Antidepressants: A Critical Commentary on the Clinical-Economic Context of Diagnosis<space/></arg><arg name="journal"><space/>The Journal of Nervous & Mental Disease<space/></arg><arg name="volume"><space/>187<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>174–80<space/></arg><arg name="year"><space/>1999<space/></arg><arg name="pmid"><space/>10086474<space/></arg><arg name="doi"><space/>10.1097/00005053-199903000-00007<space/></arg></template></extension><space/>Imipramine remained in common use and numerous successors were introduced. The use of monoamine oxidase inhibitors (MAOI) increased after the development and introduction of &quot;reversible&quot; forms affecting only the MAO-A subtype of inhibitors, making this drug safer to use.<extension extension_name='ref' name="3faces"></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Pletscher A<space/></arg><arg name="title"><space/>The discovery of antidepressants: A winding path<space/></arg><arg name="journal"><space/>Experientia<space/></arg><arg name="volume"><space/>47<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>4–8<space/></arg><arg name="year"><space/>1991<space/></arg><arg name="pmid"><space/>1999242<space/></arg><arg name="doi"><space/>10.1007/BF02041242<space/></arg></template></extension></paragraph><paragraph>By the 1960s, it was thought that the mode of action of tricyclics was to inhibit norepinephrine reuptake. However, norepinephrine reuptake became associated with stimulating effects. Later tricyclics were thought to affect<space/><link><target>serotonin</target></link><space/>as proposed in 1969 by Carlsson and Lindqvist as well as Lapin and Oxenkrug.<template><target>medical citation needed</target><arg name="date">March 2013</arg></template></paragraph><paragraph>Researchers began a process of<space/><link><target>rational drug design</target></link><space/>to isolate antihistamine-derived compounds that would selectively target these systems. The first such compound to be patented was<space/><link><target>zimelidine</target></link><space/>in 1971, while the first released clinically was<space/><link><target>indalpine</target></link>.<space/><link><target>Fluoxetine</target></link><space/>was approved for commercial use by the US<space/><link><target>Food and Drug Administration</target></link><space/>(FDA) in 1988, becoming the first<space/><link><target>Blockbuster drug</target><part>blockbuster</part></link><space/>SSRI. Fluoxetine was developed at<space/><link><target>Eli Lilly and Company</target></link><space/>in the early 1970s by Bryan Molloy,<space/><link><target>Klaus Schmiegel</target></link>, David Wong and others.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Domino EF<space/></arg><arg name="title"><space/>History of modern psychopharmacology: A personal view with an emphasis on antidepressants<space/></arg><arg name="journal"><space/>Psychosomatic Medicine<space/></arg><arg name="volume"><space/>61<space/></arg><arg name="issue"><space/>5<space/></arg><arg name="pages"><space/>591–8<space/></arg><arg name="year"><space/>1999<space/></arg><arg name="pmid"><space/>10511010<space/></arg><arg name="doi"><space/>10.1097/00006842-199909000-00002<space/></arg><arg name="url"><space/>http://www.psychosomaticmedicine.org/cgi/pmidlookup?view</arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Wong DT, Bymaster FP, Horng JS, Molloy BB<space/></arg><arg name="title"><space/>A new selective inhibitor for uptake of serotonin into synaptosomes of rat brain: 3-(p-trifluoromethylphenoxy). N-methyl-3-phenylpropylamine<space/></arg><arg name="journal"><space/>The Journal of Pharmacology and Experimental Therapeutics<space/></arg><arg name="volume"><space/>193<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>804–11<space/></arg><arg name="year"><space/>1975<space/></arg><arg name="pmid"><space/>1151730<space/></arg><arg name="url"><space/>http://jpet.aspetjournals.org/cgi/pmidlookup?view</arg></template></extension><space/>SSRIs became known as &quot;novel antidepressants&quot; along with other newer drugs such as SNRIs and<space/><link><target>Norepinephrine Reuptake Inhibitor</target><part>NRIs</part></link><space/>with various selective effects.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1016/0924-9338(96)88597-X<space/></arg><arg name="title">Tolerability and safety of novel antidepressants<space/></arg><arg name="year">1996<space/></arg><arg name="last1">Freeman<space/></arg><arg name="first1">H<space/></arg><arg name="journal">European Psychiatry<space/></arg><arg name="volume">11<space/></arg><arg name="pages">206s</arg></template></extension></paragraph><paragraph><link><target>Hypericum perforatum</target><part>St John's wort</part></link><space/>fell out of favor in most countries through the 19th and 20th centuries, except in<space/><link><target>Germany</target></link>, where<space/><link><target>Hypericum</target></link><space/>extracts were eventually licensed, packaged and prescribed. Small-scale efficacy trials were carried out in the 1970s and 1980s, and attention grew in the 1990s following a<space/><link><target>meta-analysis</target></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D<space/></arg><arg name="title"><space/>St John's wort for depression—an overview and meta-analysis of randomised clinical trials<space/></arg><arg name="journal"><space/>BMJ<space/></arg><arg name="volume"><space/>313<space/></arg><arg name="issue"><space/>7052<space/></arg><arg name="pages"><space/>253–8<space/></arg><arg name="year"><space/>1996<space/></arg><arg name="pmid"><space/>8704532<space/></arg><arg name="pmc"><space/>2351679<space/></arg><arg name="doi"><space/>10.1136/bmj.313.7052.253<space/></arg></template></extension><space/>It remains an<space/><link><target>over-the-counter drug</target></link><space/>(OTC) supplement in most countries. Research continues to investigate its active component<space/><link><target>hyperforin</target></link>, and to further understand its mode of action.<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Müller WE<space/></arg><arg name="title"><space/>Current St. John's wort research from mode of action to clinical efficacy<space/></arg><arg name="journal"><space/>Pharmacological Research<space/></arg><arg name="volume"><space/>47<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>101–9<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12543057<space/></arg><arg name="doi"><space/>10.1016/S1043-6618(02)00266-9<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Nathan PJ<space/></arg><arg name="title"><space/>Hypericum perforatum (St John's Wort): A non-selective reuptake inhibitor? A review of the recent advances in its pharmacology<space/></arg><arg name="journal"><space/>Journal of Psychopharmacology<space/></arg><arg name="volume"><space/>15<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>47–54<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="pmid"><space/>11277608<space/></arg><arg name="doi"><space/>10.1177/026988110101500109<space/></arg></template></extension></paragraph><heading level='2'>Society and culture</heading><heading level='3'>Prescription trends</heading><paragraph>In the United States, antidepressants were the most commonly prescribed medication in 2013.<extension extension_name='ref' name="AJantidepressantstatsUS"></extension><space/>Of the estimated 16 million &quot;long term&quot; (over 24 months) users, roughly 70 percent are female.<extension extension_name='ref' name="AJantidepressantstatsUS"><template><target>cite web</target><arg name="last1">White</arg><arg name="first1">Rebecca</arg><arg name="title">Waking up from sadness: Many find trouble getting off antidepressants</arg><arg name="url">http://america.aljazeera.com/articles/2014/1/22/patients-mostly-womenfindtroublegettingoffofantidepressants.html</arg><arg name="website">Al Jazeera</arg><arg name="accessdate">8 June 2014</arg></template></extension></paragraph><paragraph>In the UK, figures reported in 2010 indicated that the number of antidepressant prescribed by the<space/><link><target>National Health Service</target></link><space/>(NHS) almost doubled over a decade.<extension extension_name='ref'><template><target>cite news</target><arg name="url">http://www.guardian.co.uk/society/2010/jun/11/antidepressant-prescriptions-rise-nhs-recession<space/></arg><arg name="title">Antidepressant Use Rises as Recession Feeds Wave of Worry<space/></arg><arg name="date">11 June 2010<space/></arg><arg name="accessdate">1 July 2010<space/></arg><arg name="location">London<space/></arg><arg name="newspaper">The Guardian<space/></arg><arg name="first">Rowenna<space/></arg><arg name="last">Davis<space/></arg><arg name="archiveurl">https://web.archive.org/web/20100615165456/http://www.guardian.co.uk/society/2010/jun/11/antidepressant-prescriptions-rise-nhs-recession?<space/></arg><arg name="archivedate">15 June 2010<space/></arg><arg name="deadurl">no</arg></template></extension><space/>Further analysis published in 2014 showed that number of antidepressants dispensed annually in the community went up by 25 million in the 14 years between 1998 and 2012, rising from 15 million to 40 million. Nearly 50% of this rise occurred in the four years after the<space/><link><target>Financial crisis of 200708</target><part>2008 banking crash</part></link>, during which time the annual increase in prescriptions rose from 6.7% to 8.5%.<extension extension_name='ref'><template><target>cite web</target><arg name="last1">Spence</arg><arg name="first1">Ruth</arg><arg name="title">Focus on: Antidepressant prescribing</arg><arg name="url">http://www.qualitywatch.org.uk/focus-on/antidepressant-prescribing</arg><arg name="website">QualityWatch</arg><arg name="publisher">QualityWatch (Nuffield Trust/Health Foundation)</arg><arg name="accessdate">12 January 2015</arg></template></extension><space/>These sources also suggest that aside from the recession, other factors that may influence changes in prescribing rates may include: improvements in diagnosis, a reduction of the<space/><link><target>Social stigma</target><part>stigma</part></link><space/>surrounding mental health, broader prescribing trends, GP characteristics, geographical location and housing status. Another factor that contribute to increasing consumption of antidepressants is the fact that these medications now are used for other conditions including<space/><link><target>social anxiety</target></link><space/>and<space/><link><target>post traumatic stress</target></link>.</paragraph><heading level='3'>Most commonly prescribed</heading><paragraph><link><target>File:Sertraline2DACS2.svg</target><part>thumb</part><part>alt=</part><part>link=</part><part>Structural formula of the SSRI<space/><link><target>sertraline</target></link></part></link></paragraph><paragraph><bold>United States:</bold><space/>The most commonly prescribed antidepressants in the US retail market in 2010 were:<extension extension_name='ref'><template><target>cite web</target><arg name="title">Top 200 generic drugs by units in 2010<space/></arg><arg name="url">http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727243/article.pdf<space/></arg><arg name="format">PDF</arg><arg name="archiveurl">http://web.archive.org/web/20121215070930/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727243/article.pdf</arg><arg name="archivedate">15 December 2012</arg></template><template><target>cite web</target><arg name="title">Top 200 brand drugs by units in 2010<space/></arg><arg name="url">http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727256/article.pdf<space/></arg><arg name="format">PDF</arg><arg name="archiveurl">http://web.archive.org/web/20120422181417/http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/252011/727256/article.pdf</arg><arg name="archivedate">22 April 2012</arg></template></extension></paragraph><table class="wikitable sortable"><tablerow><tablecell><bold>Drug name</bold></tablecell><tablecell><bold>Commercial name</bold></tablecell><tablecell><bold>Drug class</bold></tablecell><tablecell><bold>Total prescriptions</bold></tablecell></tablerow><tablerow><tablecell><link><target>Sertraline</target></link></tablecell><tablecell>Zoloft</tablecell><tablecell><link><target>SSRI</target></link></tablecell><tablecell>33,409,838</tablecell></tablerow><tablerow><tablecell><link><target>Citalopram</target></link></tablecell><tablecell>Celexa</tablecell><tablecell><link><target>SSRI</target></link></tablecell><tablecell>27,993,635</tablecell></tablerow><tablerow><tablecell><link><target>Fluoxetine</target></link></tablecell><tablecell>Prozac</tablecell><tablecell><link><target>SSRI</target></link></tablecell><tablecell>24,473,994</tablecell></tablerow><tablerow><tablecell><link><target>Escitalopram</target></link></tablecell><tablecell>Lexapro</tablecell><tablecell><link><target>SSRI</target></link></tablecell><tablecell>23,000,456</tablecell></tablerow><tablerow><tablecell><link><target>Trazodone</target></link></tablecell><tablecell>Desyrel</tablecell><tablecell><link><target>Serotonin antagonist and reuptake inhibitor</target><part>SARI</part></link></tablecell><tablecell>18,786,495</tablecell></tablerow><tablerow><tablecell><link><target>Duloxetine</target></link></tablecell><tablecell>Cymbalta</tablecell><tablecell><link><target>Serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link></tablecell><tablecell>14,591,949</tablecell></tablerow><tablerow><tablecell><link><target>Paroxetine</target></link></tablecell><tablecell>Paxil</tablecell><tablecell><link><target>SSRI</target></link></tablecell><tablecell>12,979,366</tablecell></tablerow><tablerow><tablecell><link><target>Amitriptyline</target></link></tablecell><tablecell>Elavil</tablecell><tablecell><link><target>tricyclic antidepressant</target><part>TCA</part></link></tablecell><tablecell>12,611,254</tablecell></tablerow><tablerow><tablecell><link><target>Venlafaxine</target></link><space/>XR</tablecell><tablecell>Effexor XR</tablecell><tablecell><link><target>Serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link></tablecell><tablecell>7,603,949</tablecell></tablerow><tablerow><tablecell><link><target>Bupropion</target></link><space/>XL</tablecell><tablecell>Wellbutrin XL</tablecell><tablecell><link><target>Norepinephrine-dopamine reuptake inhibitor</target><part>NDRI</part></link></tablecell><tablecell>7,317,814</tablecell></tablerow><tablerow><tablecell><link><target>Mirtazapine</target></link></tablecell><tablecell>Remeron</tablecell><tablecell><link><target>Tetracyclic antidepressant</target><part>TeCA</part></link></tablecell><tablecell>6,308,288</tablecell></tablerow><tablerow><tablecell><link><target>Venlafaxine</target></link><space/>ER</tablecell><tablecell>Effexor XR</tablecell><tablecell><link><target>Serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link></tablecell><tablecell>5,526,132</tablecell></tablerow><tablerow><tablecell><link><target>Bupropion</target></link><space/>SR</tablecell><tablecell>Wellbutrin SR</tablecell><tablecell><link><target>Norepinephrine-dopamine reuptake inhibitor</target><part>NDRI</part></link></tablecell><tablecell>4,588,996</tablecell></tablerow><tablerow><tablecell><link><target>Desvenlafaxine</target></link></tablecell><tablecell>Pristiq</tablecell><tablecell><link><target>Serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link></tablecell><tablecell>3,412,354</tablecell></tablerow><tablerow><tablecell><link><target>Nortriptyline</target></link></tablecell><tablecell>Sensoval</tablecell><tablecell><link><target>tricyclic antidepressant</target><part>TCA</part></link></tablecell><tablecell>3,210,476</tablecell></tablerow><tablerow><tablecell><link><target>Bupropion</target></link><space/>ER</tablecell><tablecell>Wellbutrin XL</tablecell><tablecell><link><target>Norepinephrine-dopamine reuptake inhibitor</target><part>NDRI</part></link></tablecell><tablecell>3,132,327</tablecell></tablerow><tablerow><tablecell><link><target>Venlafaxine</target></link></tablecell><tablecell>Effexor</tablecell><tablecell><link><target>Serotonin-norepinephrine reuptake inhibitor</target><part>SNRI</part></link></tablecell><tablecell>2,980,525</tablecell></tablerow><tablerow><tablecell><link><target>Bupropion</target></link></tablecell><tablecell>Wellbutrin IR</tablecell><tablecell><link><target>Norepinephrine-dopamine reuptake inhibitor</target><part>NDRI</part></link></tablecell><tablecell>753,516</tablecell></tablerow></table><paragraph><bold>Netherlands:</bold><space/>In the Netherlands,<space/><link><target>paroxetine</target></link>, marketed as Seroxat among generic preparations, is the most prescribed antidepressant, followed by<space/><link><target>amitriptyline</target></link>,<space/><link><target>citalopram</target></link><space/>and<space/><link><target>venlafaxine</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.gipdatabank.nl/index.asp?scherm</arg><arg name="title">GIPdatabank<space/></arg><arg name="publisher">Gipdatabank.nl<space/></arg><arg name="accessdate">6 November 2008<space/></arg><arg name="archiveurl">https://web.archive.org/web/20081206123718/http://www.gipdatabank.nl/index.asp?scherm</arg><arg name="archivedate">6 December 2008<space/></arg><arg name="deadurl">no</arg></template></extension></paragraph><heading level='3'>Social science perspective</heading><paragraph>In looking at the issue of antidepressant use, some academics have highlighted the need to examine the use of antidepressants and other medical treatments in cross-cultural terms, due to the fact that various cultures prescribe and observe different manifestations, symptoms, meanings and associations of depression and other medical conditions within their populations.<extension extension_name='ref' name="Ecks_2005"><template><target>cite journal</target><arg name="author"><space/>Ecks S<space/></arg><arg name="title"><space/>Pharmaceutical Citizenship: Antidepressant Marketing and the Promise of Demarginalization in India<space/></arg><arg name="journal"><space/>Anthropology & Medicine<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="volume"><space/>12<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>239–254<space/></arg><arg name="doi">10.1080/13648470500291360</arg></template></extension><extension extension_name='ref' name="Lock_2010"><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last1"><space/>Lock M, Nguyen VK<space/></arg><arg name="title"><space/>An anthropology of biomedicine<space/></arg><arg name="date"><space/>2010<space/></arg><arg name="publisher"><space/>Wiley-Blackwell<space/></arg><arg name="location"><space/>Chichester, West Sussex<space/></arg><arg name="isbn"><space/>1-4051-1071-6<space/></arg><arg name="edition"><space/>1st</arg><arg name="chapter">"Local Biologies and Human Difference<space/></arg><arg name="pages"><space/>83–109<space/></arg></template></extension><space/>These cross-cultural discrepancies, it has been argued, then have implications on the perceived efficacy and use of antidepressants and other strategies in the treatment of depression in these different cultures.<extension extension_name='ref' name="Ecks_2005"></extension><extension extension_name='ref' name="Lock_2010"></extension><space/>In India antidepressants are largely seen as tools to combat marginality, promising the individual the ability to re-integrate into society through their usea view and association not observed in the West.<extension extension_name='ref' name="Ecks_2005"></extension></paragraph><heading level='3'>Environmental impacts</heading><paragraph>Somewhat less than 10% of orally administered fluoxetine is excreted from humans unchanged or as<space/><link><target>glucuronide</target></link>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.science.smith.edu/departments/Biochem/Chm_357/Articles/SSRIs.pdf<space/></arg><arg name="title">Pharmacokinetics of selective serotonin reuptake inhibitors<space/></arg><arg name="format"><space/></arg><arg name="work"><space/></arg><arg name="accessdate"><space/></arg><arg name="archiveurl">https://web.archive.org/web/20140523225824/http://www.science.smith.edu/departments/Biochem/Chm_357/Articles/SSRIs.pdf<space/></arg><arg name="archivedate">23 May 2014</arg></template></extension><extension extension_name='ref' name="pmid17160491"><template><target>cite journal</target><arg name="author"><space/>Nentwig G<space/></arg><arg name="title"><space/>Effects of pharmaceuticals on aquatic invertebrates. Part II: the antidepressant drug fluoxetine<space/></arg><arg name="journal"><space/>Arch. Environ. Contam. Toxicol.<space/></arg><arg name="volume"><space/>52<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>163–70<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17160491<space/></arg><arg name="doi"><space/>10.1007/s00244-005-7190-7<space/></arg></template></extension><space/>Because most antidepressants function by inhibiting the reuptake of neurotransmitters serotonin, dopamine, and norepinepherine<extension extension_name='ref' name="pmid17690258"><template><target>cite journal</target><arg name="author"><space/>Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME, Wang DN<space/></arg><arg name="title"><space/>LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake<space/></arg><arg name="journal"><space/>Science<space/></arg><arg name="volume"><space/>317<space/></arg><arg name="issue"><space/>5843<space/></arg><arg name="pages"><space/>1390–3<space/></arg><arg name="year"><space/>2007<space/></arg><arg name="pmid"><space/>17690258<space/></arg><arg name="pmc"><space/>3711652<space/></arg><arg name="doi"><space/>10.1126/science.1147614<space/></arg></template></extension><space/>these drugs can interfere with natural neurotransmitter levels in other organisms impacted by indirect exposure.<extension extension_name='ref'><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="editor"><space/>Daughton CG, Jones-Lepp TJ<space/></arg><arg name="title"><space/>Pharmaceuticals and personal care products in the environment: scientific and regulatory issues<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="publisher"><space/>American Chemical Society<space/></arg><arg name="location"><space/>Washington, DC<space/></arg><arg name="isbn"><space/>978-0-8412-3739-1<space/></arg><arg name="chapter"><space/>Antidepressants in Aquatic Organisms: A Wide Range of Effects<space/></arg><arg name="author"><space/>Fong PP<space/></arg><arg name="pages"><space/>264–281<space/></arg></template></extension><space/>Antidepressants fluoxetine and sertraline have been detected in aquatic organisms residing in effluent dominated streams.<extension extension_name='ref' name="pmid15720009"><template><target>cite journal</target><arg name="author"><space/>Brooks BW, Chambliss CK, Stanley JK, Ramirez A, Banks KE, Johnson RD, Lewis RJ<space/></arg><arg name="title"><space/>Determination of select antidepressants in fish from an effluent-dominated stream<space/></arg><arg name="journal"><space/>Environ. Toxicol. Chem.<space/></arg><arg name="volume"><space/>24<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>464–9<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>15720009<space/></arg><arg name="doi"><space/>10.1897/04-081r.1<space/></arg></template></extension><space/>The presence of antidepressants in surface waters and aquatic organisms has caused concern because ecotoxicological effects to aquatic organisms due to fluoxetine exposure have been demonstrated.<extension extension_name='ref' name="pmid16257063"><template><target>cite journal</target><arg name="author"><space/>Fent K, Weston AA, Caminada D<space/></arg><arg name="title"><space/>Ecotoxicology of human pharmaceuticals<space/></arg><arg name="journal"><space/>Aquat. Toxicol.<space/></arg><arg name="volume"><space/>76<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>122–59<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16257063<space/></arg><arg name="doi"><space/>10.1016/j.aquatox.2005.09.009<space/></arg></template></extension><space/>Coral reef fish have been demonstrated to modulate aggressive behavior through serotonin.<extension extension_name='ref'><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="author"><space/>Winberg S, Carter CG, McCarthy JD, He XY, Nilsson GE, Houlihan DF<space/></arg><arg name="title"><space/>Feeding rank and brain serotonergic activity in rainbow trout ''Onchorhynchus my kiss''<space/></arg><arg name="journal"><space/>J. Exp. Biol.<space/></arg><arg name="volume"><space/>179<space/></arg><arg name="year"><space/>1993<space/></arg><arg name="pages"><space/>197–211<space/></arg></template></extension></paragraph><paragraph>Exposure to fluoxetine has been demonstrated to increase serotonergic activity in fish, subsequently reducing aggressive behavior.<extension extension_name='ref' name="pmid12954414"><template><target>cite journal</target><arg name="author"><space/>Perreault HA, Semsar K, Godwin J<space/></arg><arg name="title"><space/>Fluoxetine treatment decreases territorial aggression in a coral reef fish<space/></arg><arg name="journal"><space/>Physiol. Behav.<space/></arg><arg name="volume"><space/>79<space/></arg><arg name="issue"><space/>4–5<space/></arg><arg name="pages"><space/>719–24<space/></arg><arg name="year"><space/>2003<space/></arg><arg name="pmid"><space/>12954414<space/></arg><arg name="doi"><space/>10.1016/S0031-9384(03)00211-7<space/></arg></template></extension><space/>Artificially increasing serotonin levels in crustaceans can temporarily reverse social status and turn subordinates into aggressive and territorial dominant males.<extension extension_name='ref' name="pmid9159179"><template><target>cite journal</target><arg name="author"><space/>Huber R, Smith K, Delago A, Isaksson K, Kravitz EA<space/></arg><arg name="title"><space/>Serotonin and aggressive motivation in crustaceans: altering the decision to retreat<space/></arg><arg name="journal"><space/>Proc. Natl. Acad. Sci. U.S.A.<space/></arg><arg name="volume"><space/>94<space/></arg><arg name="issue"><space/>11<space/></arg><arg name="pages"><space/>5939–42<space/></arg><arg name="year"><space/>1997<space/></arg><arg name="pmid"><space/>9159179<space/></arg><arg name="pmc"><space/>20885<space/></arg><arg name="doi"><space/>10.1073/pnas.94.11.5939<space/></arg></template></extension><space/>Perinatal exposure to fluoxetine at relevant environmental concentrations has been shown to lead to significant modifications of memory processing in 1-month-old cuttlefish.<extension extension_name='ref' name="pmid23474317"><template><target>cite journal</target><arg name="author"><space/>Di Poi C, Darmaillacq AS, Dickel L, Boulouard M, Bellanger C<space/></arg><arg name="title"><space/>Effects of perinatal exposure to waterborne fluoxetine on memory processing in the cuttlefish Sepia officinalis<space/></arg><arg name="journal"><space/>Aquat. Toxicol.<space/></arg><arg name="volume"><space/>132–133<space/></arg><arg name="issue"><space/></arg><arg name="pages"><space/>84–91<space/></arg><arg name="year"><space/>2013<space/></arg><arg name="pmid"><space/>23474317<space/></arg><arg name="doi"><space/>10.1016/j.aquatox.2013.02.004<space/></arg></template></extension><space/>This impairment may disadvantage cuttlefish and decrease their survival.</paragraph><heading level='2'>See also</heading><paragraph><template><target>Commons category</target><arg>Antidepressants</arg></template><template><target>Wiktionary</target><arg>antidepressant</arg></template></paragraph><list type='bullet'><listitem><link><target>Antidepressants in Japan</target></link></listitem><listitem><link><target>Atypical depression</target></link></listitem><listitem><link><target>Depression and natural therapies</target></link></listitem><listitem><link><target>Discovery and development of dual serotonin and norepinephrine reuptake inhibitors</target></link></listitem><listitem><italics><link><target>Listening to Prozac</target></link></italics><space/>by Peter Kramer</listitem><listitem><italics><link><target>Anatomy of an Epidemic</target></link></italics><space/>by Robert Whittaker</listitem></list><paragraph><template><target>clear</target></template></paragraph><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>30em</arg></template></paragraph><heading level='2'>Additional reading</heading><list type='bullet'><listitem><template><target>cite book</target><arg name="name-list-format"><space/>vanc<space/></arg><arg name="last">Stahl<space/></arg><arg name="first">Stephen M.<space/></arg><arg name="title">Psychopharmacology of Antidepressants<space/></arg><arg name="publisher">Informa Healthcare<space/></arg><arg name="year">1997<space/></arg><arg name="isbn">978-1-85317-513-8</arg></template></listitem></list><paragraph><template><target>Antidepressants</target></template><template><target>Major drug groups</target></template></paragraph><paragraph><template><target>Authority control</target></template></paragraph><paragraph><link><target>Category:Antidepressants</target><part></part></link><link><target>Category:Psychiatric instruments: depression</target></link></paragraph></article>